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ABSTRACT 
CHARACTERIZING THE GUT MICROBIOTA DURING PLASMODIUM 
INFECTION AND ANTIMALARIAL TREATMENT 
Joshua E. Denny 
December 14, 2018 
 
Plasmodium, the parasitic cause of malaria, is a global pathogen, annually 
causing 216 million infections and 445,000 deaths. As drug resistance continues 
develop and no effective vaccine is available, it is critical to understand the 
factors underlying the severity of this disease. Plasmodium is an extra-
gastrointestinal tract infection where the parasite infects red blood cells causing 
clinical malaria. However, recent publications have pointed to interactions 
between the gut microbiota and malaria. With this in mind, the role of the gut 
microbiota in malaria infection was studied. C57BL/6 mice from different vendors 
displayed differential resistance and susceptibility to severe malaria, and cecal 
contents transplanted from these mice to germ-free mice recapitulated the 
observed phenotypes. Similarly, resistant mice possessed a much more robust 
humoral immune response than susceptible mice, which is critical for 
Plasmodium clearance. When the cecal contents from resistant and susceptible 
mice were sequenced, Lactobacillus and Bifidobacterium genera were enriched 
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in resistant mice. Moreover, treating susceptible mice with probiotics containing 
these bacterial genera after antibiotic administration led to a lower parasite 
burden. These observations point to a previously unknown role for the microbiota 
in modulating the severity of malaria. 
To further characterize the interactions between the host and gut 
microbiota in malaria, different components of gut homeostasis were investigated 
in both mild and severe disease. While intestinal permeability increased in both 
resistant and susceptible mice, there were no significant differences between the 
two groups. However, susceptible mice were shown to have greater numbers of 
lamina propria immune cells as well as greater abundances of cecal metabolites 
and bile acids during infection compared to resistant mice. Consistent with the 
decreased abundance of bile acids, histology showed much greater and 
prolonged damage and hemozoin deposition in the livers of susceptible mice 
compared to resistant mice. Despite these differences, the microbiota 
composition of resistant and susceptible mice became more similar during 
infection, although these changes were not associated with susceptibility or 
resistance when the altered cecal contents were transferred into germ-free mice. 
However, there were distinct differences in the functional capacity of the resistant 
and susceptible microbiota during infection. Susceptible mice showed significant 
increases in genes related to bacterial motility and flagellar assembly. Overall, 
there are profound differences in gut homeostasis during severe and mild Py 
infection. 
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Finally, it was investigated whether antimalarial drugs, particularly 
clinically relevant artemisinin combination therapies (ACTs), could disrupt the gut 
microbiota. As previously shown, the composition of the gut microbiota alone can 
modulate the severity of Py infection; if ACTs change the microbiota composition, 
future infections could be more severe. To test this hypothesis, two common 
ACTs, artesunate plus amodiaquine and artemether plus lumefantrine, were 
used to orally treat mice while fecal pellets were collected to characterize the gut 
microbiota before and after treatment. After either ACT treatment, the overall 
species abundance in mice was similar to baseline. While alpha diversity 
remained unchanged by any treatment, there were minor, inconsistent changes 
in beta diversity that returned to baseline. With these findings, it does not appear 
that ACTs change the gut microbiota. 
This work has greatly increased the scientific knowledge concerning the 
three-fold interaction between host, gut microbiota, and Plasmodium. While much 
work still needs to be done, these findings can provide a contextual foundation 
on which future work can be built.  
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Plasmodium Life Cycle 
 Malaria is a global health crisis, with approximately 2 million infections and 
400,000 deaths annually, with the majority occurring in Africa in children under 
the age of 51,2. Plasmodium, the causative agent of malaria, is a single-celled 
protozoan parasite with a multi-stage life cycle that occurs in the vertebrate host 
and the arthropod vector, generally a mosquito. In humans, the cycle begins 
when a female Anopheles mosquito takes a blood meal from a human host and 
injects Plasmodium sporozoites into the skin of the human host3. The sporozoites 
migrate to the bloodstream and are carried to the liver. At this stage, the 
infectious dose of sporozoites can be quite small; as few as 100 sporozoites can 
cause disease4. The sporozoites invade hepatocytes, where they differentiate 
into merozoites. This stage of disease is clinically silent with no symptoms of 
infection. Once the merozoites have matured, they exit the hepatocyte in 
membrane bound vesicles, called merosomes5. Upon rupture of the merosome 
membrane, merozoites enter the bloodstream where they will infect red blood 
cells (RBCs). Some Plasmodium species will infect differentially developed 
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RBCs. For example, P. falciparum will infect RBCs at any developmental stage, 
while others, like P. vivax, will only infect immature reticulocytes6. Infection of 
RBCs has several steps: attachment, apical reorientation, junction formation, and 
invasion7. Initially, the merozoite must reach and attach to the RBC; once the 
merozoite is attached, it must reorient itself as the apical end must face the cell 
membrane for junction formation. Formation of the tight junction will “seal” the 
two cells together; as the merozoite moves into the RBC, the RBC membrane will 
fold around the merozoite to form the parasitophorous vacuole, where the 
parasite will reproduce8. At this point, most parasites will continue asexual 
reproduction, proliferating until lysing the RBC and infecting new RBCs. 
However, a few parasites will differentiate into gametocytes, which can be 
ingested by a mosquito, undergo sexual reproduction, and continue the 
Plasmodium life cycle in a new host8.  
Plasmodium species can infect many different vertebrates, including 
humans, non-human primates, rodents, birds, and lizards9. The major 
Plasmodium species that cause morbidity and mortality in humans are P. 
falciparum (Pf) and P. vivax (Pv). Whereas P. ovale, P. knowlesi, and P. malariae 
also infect humans, they are of less clinical significance. Geographically, 
Plasmodium is restricted to tropical and subtropical regions due to distribution of 
mosquito vectors such as Anopheles gambiae and climate conditions with 
appropriate rainfall and temperature10. In areas with rainy seasons, malaria 
transmission is restricted seasonally as the mosquito vectors require standing 
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water for development10. Generally, most human-specific Plasmodium species 
occupy the same geographic areas, and people can be infected with more than 
one species at a time3. However, Pv is restricted from sub-Saharan Africa due to 
the lack of the Duffy antigen receptor on RBCs in people of African descent; this 
receptor is required for Pv to invade RBCs11. Due to this restriction, Pf is the 
dominant Plasmodium species in sub-Saharan Africa. One other significant 
difference between Pf and Pv is that Pv infection can relapse, which is the re-
emergence of merozoites after the primary parasite burden has been cleared12,13. 
During the Pv liver stage of infection, not all of the parasites differentiate into 
merozoites; some differentiate into hypnozoites that can remain dormant in the 
liver for months or even years after infection, the length of which can depend on 
the climate and the size of sporozoite inoculation14,15.  
There are also several rodent-specific species of Plasmodium which are 
used as models for human malaria, the most common of which are P. berghei 
ANKA, P. yoelii, and P. chabaudi. Certain aspects of malaria infection are 
associated with specific mouse models. For example, cerebral malaria, which is 
one of the most lethal complications of infection, can be modeled by infecting 
C57BL/6 mice with Plasmodium berghei ANKA; approximately one week after 
infection, mice will begin to develop symptoms such as leaning, loss of balance, 
and paralysis followed by 100% mortality within 10 days of infection16. The 
mouse model recapitulates many of the mechanisms seen in human cerebral 
malaria, such as sequestration of parasitized RBCs (pRBCs) and localized 
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inflammation17. The mechanism for these symptoms is discussed in more detail 
below. P. chabaudi infection, on the other hand, is generally non-lethal, and can 
model a more general human Plasmodium infection6. P. chabaudi, like Pf, infects 
RBCs at any stage of development and also reproduces many of the same 
pathological features as Pf or Pv, such as anemia and splenomegaly as well as a 
similar immune response6. One interesting feature of P. chabaudi that is not 
present in other rodent models is recrudescence of blood stage parasite burden, 
although it is more limited compared to Pf. Finally, P. yoelii (Py) can be used to 
model the pathology and human immune response to Pf, particularly the humoral 
response18. Py has both lethal and non-lethal strains, 17XL and 17XNL, 
respectively; the lethality of Py 17XL is multifactorial, but can include the 
induction of cerebral malaria and inflammation18,19. Mice infected with Py 17XNL 
develop sterilizing immunity to the parasite, and in this regard are considered 
good models for Pf vaccine development18. 
 
Host Response to Plasmodium Infection 
Clinically, Plasmodium infections are silent with no symptoms until the 
blood stage, where the parasite undergoes asexual replication. Once in the blood 
stage, common symptoms of uncomplicated malaria include fever and anemia; in 
complicated and severe cases, respiratory distress, coma or impaired 
consciousness, and severe anemia can be observed3. While the mortality rate for 
uncomplicated malaria is low, especially if treated with antimalarial drugs, the 
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mortality rate for complicated severe malaria is estimated to be 90% if untreated 
and 20% if hospitalized20,21. However, the underlying pathology of these 
symptoms cannot be pinned solely on Plasmodium and its lytic behavior as host 
immunopathology has also been shown to play a role. During infection, 
Plasmodium causes a general inflammatory phenotype by inducing the 
production of inflammatory cytokines22. These cytokines, particularly tumor 
necrosis factor (TNF) family members, contribute to malaria symptoms, as 
administering recombinant TNF to naïve mice produces many of the same 
symptoms as malaria22. In a parallel process called sequestration, pRBCs will 
adhere to the host endothelium, particularly in the microvasculature; this can 
obstruct flow and lead to inflammatory cytokine and cell adhesion molecule 
(CAM) expression by the endothelial cells23,24. Several downstream effects of this 
response are increasing vascular permeability, leukocyte recruitment, and local 
ischemia and tissue damage23,24. Depending on the site of sequestration, the 
pathology will take different forms: sequestration in the intestinal 
microvasculature can lead to gastrointestinal symptoms such as diarrhea, while 
sequestration in the brain can lead to cerebral malaria, which is one of the more 
severe presentations and can lead to long-term neurological sequalae even after 
resolution of disease23,25.  
While the immune system can be detrimental during malaria, it is critical 
for the resolution of infection. Both the innate and adaptive responses to 
Plasmodium play a role in resolution of blood-stage malaria. Natural killer (NK) 
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cells produce interferon gamma (IFN𝛾) early in the infection, which correlates 
with resistance to malaria26,27. NK cell responses appear to be driven by IL-12 
produced by other cell populations like monocytes and dendritic cells (DCs)28. 
While NK cells may not be the first to respond, they are early responders to 
Plasmodium infection and their activation correlates with protection. 
 Gamma delta T cells (TCR𝛾𝛿) are innate-like T cell subsets that can have 
various functions depending on both differentiation and received signals, such as 
immunity to pathogens or tissue repair, and in many ways can act as a bridge 
between innate and adaptive immunity29. In some cases, TCR𝛾𝛿 cells can be the 
dominant producers of cytokines compared to CD4 or CD8 T cells30. During 
Plasmodium infection, a TCR𝛾𝛿 subset can produce IFN𝛾 early in the infection to 
enhance the immune response, particularly differentiation and proliferation of 
germinal center B cells and T follicular helper cells29,31,32. Another subset can 
produce IL-17 in a Toll-like receptor-dependent manner, which can enhance the 
pathogen clearance and the humoral immune response in multiple infections, not 
just Plasmodium30,33,34. 
 Macrophages have dual roles in malaria infection, first acting as antigen 
presenting cells (APCs) but also phagocytosing infected RBCs and clearing them 
from circulation in a typically non-inflammatory fashion28. This occurs mainly 
through interactions with Plasmodium erythrocyte membrane protein 1 (EMP1) 
which is expressed on pRBCs and is anti-inflammatory35. However, 
macrophages can detect malarial DNA bound to hemozoin during phagocytosis, 
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which will induce a strong pro-inflammatory response and can cause immune 
pathology36. Like macrophages, monocytes can also produce an anti-
inflammatory response to EMP135. However, it has also been shown that early 
after Plasmodium infection, monocytes infiltrate into the lamina propria of the 
intestine and cause inflammatory damage37,38. Plasmodium can also limit 
neutrophil populations, which can make patients susceptible to secondary 
infections39. 
 While these innate populations can in some ways bridge the innate and 
adaptive arms of the immune system during Plasmodium infection, dendritic cells 
(DCs) perform the majority of antigen presentation to T cells40. Generally, and 
unsurprisingly, dysregulation of DC antigen presentation is associated with 
morbidity and mortality during Plasmodium infection41. Studies looking at more 
particular aspects of DC function have been mixed and limited: for example, 
whether the parasite inhibits DC maturation. One study found in vitro that pRBCs 
bind to CD36 on DCs and inhibit MHCII expression and thus antigen presentation 
and T cell activation, while another study found that exposure to pRBCs did not 
affect the ability of DCs to promote a robust T cell response to malaria42,43. 
Despite conflicting data about the effect of malaria on DCs, antigen presentation 
to T cells is critical for parasite clearance. 
In particular, the humoral immune response is critical for clearance of 
blood-stage malaria44,45. To generate Plasmodium-specific antibodies, both T 
follicular helper (Tfh) cells and germinal center B (GC B) cells have to be 
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activated and form germinal centers. Interactions between the Tfh cells and GC 
B cells lead to somatic hypermutation and class switching from IgM to IgG, both 
of which enhance the antibody-mediated clearance of the parasite46. Common 
antibody targets of blood stage parasites include merozoite surface proteins 1 
and 3 (MSP1 and MSP3) as well as apical membrane antigen 1 (AMA1), all of 
which are involved in parasite invasion of RBCs47,48. Trafficking of sporozoites 
from the dermis to the liver can be inhibited by sporozoite-specific antibodies 
against antigens such as circumsporozoite protein49. Antibodies can also target 
pRBCs themselves for opsonization and destruction by phagocytes, as well as 
inhibition of sequestration48. Like other aspects of anti-Plasmodium immunity, the 
parasite can modulate the host antibody response. It has been observed in 
humans that B cell memory is impaired during malaria infection, as antibody 
responses are short-lived and immunity to malaria is acquired gradually, 
particularly in areas of seasonal malaria transmission46,50. Both T and B cells can 
display “exhausted” phenotypes, characterized by a hypo-responsiveness to 
malaria and expression of PD-L1 and LAG3 on CD4 T cells51,52. In humans, CD4 
T cell expression of PD-L1 and LAG3 inversely correlates with B cell memory 
responses; this contributes to the difficulty in acquiring clinical immunity to 
malaria in areas with chronic Plasmodium exposure51,52. Blocking PD-L1 and 
LAG3 on T cells can reverse exhaustion and promote antibody-mediated 
Plasmodium clearance51,52. Additionally, another mechanism Plasmodium can 
use to modulate humoral immunity in P. berghei ANKA infection in C57BL/6 mice 
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is induction of a large IFN𝛾 and tumor necrosis factor-dependent inflammatory 
response to disrupt GC architecture and inhibit Tfh differentiation, both of which 
lead to an impaired humoral response53. Due to the prevalence of complicated 
malaria and the difficulty in achieving clinical immunity to Plasmodium, 
antimalarial drug treatments are essential for reducing malaria-associated 
morbidity and mortality. 
   
Treatment of Plasmodium Infections 
 Frontline treatment of malaria is done with artemisinin combination 
therapies (ACTs). Artemisinin and its derivatives, artemether and artesunate, 
have a very rapid metabolism and half-life within the host; to complement this, 
longer-acting antimalarial drugs are combined to maximize the clinical efficacy 
the treatments. Two of the most common combinations are artemether paired 
with lumefantrine and artesunate paired with amodiaquine. ACTs are effective 
against the asexual stages of the Plasmodium life cycle, which translates 
clinically to the blood stage of infection. The World Health Organization 
recommends using the oral route of treatment, although ACTs can also be given 
intravenously, intramuscularly, or rectally20.  
 While ACTs have proven to be effective at treating malaria, the associated 
mechanisms of action for the drugs are unknown, to certain degrees. 
Lumefantrine and amodiaquine are thought to interfere with the ability of 
Plasmodium to metabolize heme, which is toxic to the parasite54. More is known 
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about the mechanism of artemisinin and its derivatives. These drugs have been 
shown to be multifaceted in their effects on the host, but the major role these 
drugs appear to play is causing cellular damage and inhibiting proteasome 
function in Plasmodium55. This leads to the buildup of damaged proteins, 
endoplasmic reticulum stress, and induction of apoptosis, killing the parasite56. 
While artemisinin and derivatives have been relatively well characterized in their 
interactions with Plasmodium, much less is known about how artemisinin 
interacts with bacteria, particularly since the oral route is preferred for ACT 
administration. Artemisinin has been shown to kill Helicobacter pylori, but 
otherwise is not effective at killing various bacteria and fungi in vitro, such as 
Staphylococcus aureus or Bacillus subtilis57,58. Other tested artemisinin 
derivatives were shown to have moderate antibacterial and lesser antifungal 
properties, but most have not been approved for clinical use57. 
 
The Microbiota 
 The microbiome is the collection of microbes and their genetic material 
associated with a host, and is typically delineated by occupied niche, such as 
skin and gut microbiome, while the microbiota refers to the collection of 
organisms. While bacteria have been the most widely studied, other organisms 
such as fungi and viruses are commensal as well. In the past, studying many of 
the microbiota constituents was out of reach due to their inability to be grown in 
lab conditions. However, the rise of 16S rRNA sequencing has led to culture-
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independent methods of characterizing the microbiota. Variable regions within 
the 16S rRNA gene are highly conserved between bacterial species and can be 
used to reliably identify bacterial taxa for phylogenetic analyses. Coupled with the 
low cost of DNA sequencing, the human and murine microbiomes have been well 
characterized, both in healthy conditions as well as in some disease states.  
 The gut microbiota can be influenced by many factors which can affect the 
composition or function of the microbiota, with two of the most studied being 
antibiotic treatment and diet. Given orally, antibiotics can act directly on the 
bacteria in the gut; given the right antibiotics and dosing, a majority of the 
microbiota can be depleted59. However, even subclinical doses of antibiotics can 
disrupt the microbiota and can contribute to the development of obesity or 
allergies60,61. Disruption of the microbiota can lead to disease as pathobionts in 
the gut such as Clostridium difficile or Enterococcus faecium can outgrow and 
establish niches59,62.  
 The effect of host diet on the microbiota has also been studied 
extensively. Like antibiotics, shifts in diet can significantly reshape the microbiota. 
Adopting an animal-based diet, for example, can shift the microbiota composition 
to a more bile-tolerant community in as little as 48 hours63. Diet-induced shifts in 
the microbiota can also be reversible. Different types of diet can have positive or 
negative effects, as different nutrients can be metabolized differently. For 
example, a high salt diet in mice has been shown to decrease Lactobacillus 
murinus in the gut; L. murinus can reduce Th17 cell numbers in the intestine and 
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ameliorate experimental autoimmune encephalitis and salt-induced 
hypertension64. Conversely, a diet high in dietary fiber has been shown to be 
beneficial through fermentation and production of short-chain fatty acids (SCFAs) 
like butyrate and propionate65. SCFAs, particularly butyrate, have been shown to 
have many different effects on the host. Butyrate can induce an anti-inflammatory 
response in the intestine by acting as a histone deacetylase and regulating gene 
expression, primarily in macrophages and regulatory T cells (Tregs)65. 
Modulation of the gut microbiota, through antibiotics or diet, has diverse effects 
on the host. 
  
The Gut Microbiota and Infectious Disease 
Due to the close nature of the relationship between the microbiota and the 
host, the microbiota has been investigated in infectious disease. As mentioned 
previously, C. difficile is a pathobiont in the gut microbiota and can take 
advantage of microbial and metabolic disruptions in the gut to proliferate66. Once 
C. difficile has established a niche in the host, it can cause abdominal pain and 
diarrhea67. While antibiotics can be used to treat acute C. difficile, recurrent 
infections can occur and antibiotic treatment can fail68. One overwhelmingly 
effective method of treating C. difficile infection is fecal microbiota transplantation 
(FMT)68. FMT is fairly straightforward, involving isolation of bacteria from donor 
feces and encapsulation for patient ingestion; a single treatment has been shown 
to resolve C. difficile infection in 70% of patients while that rate increases to 90% 
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after a second FMT68. One reason for the success of FMT is the increase in 
overall bacterial diversity and abundance, particularly in the Bacteroides genus69. 
The increase in diversity can restore metabolic homeostasis in the gut, 
particularly secondary bile acid biosynthesis which confers resistance to C. 
difficile infection70. While C. difficile is an intestinal infection, the gut microbiota 
can also affect extra-intestinal infections as well. 
One extra-intestinal disease that has been investigated is influenza virus, 
which despite infecting the respiratory tract, can be affected by the gut 
microbiota. Influenza can occasionally cause gastrointestinal symptoms like 
diarrhea. Treating mice with antibiotics has been shown to impair the ability of 
the host to form a sufficient virus-specific immune response to clear the virus71,72. 
Compared to untreated mice, antibiotic-treated mice have an impaired 
inflammatory response as well as significantly lower innate or adaptive virus-
specific responses71,72. Conversely, influenza infection can change the 
composition of the microbiota, decreasing the abundance of Lactobacillus 
species and segmented filamentous bacteria but increasing the abundance of the 
Enterobacteriaceae family members and Sphingomonas species71,73. This 
dysbiosis was required for gastrointestinal symptoms. The dysbiosis, in turn, is 
caused by the expansion of inflammatory Th17 cells in the intestine that respond 
to the IFN𝛾 produced by lung-derived CD4+ T cells73. Overall, the gut microbiota 
is beneficial to the host, helping produce a robust anti-influenza immune 
response, but can itself be affected by influenza-induced inflammation. 
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 The microbiota has been shown to be important during Plasmodium 
infection. Members of the gut microbiota express the glycan Galα1-3Galβ1-
4GlcNAc-R (alpha-gal) on their surface, which induce anti-alpha-gal antibodies74. 
Plasmodium sporozoites, but not merozoites, also express alpha-gal on their 
surface, and the presence of anti-alpha-gal IgM antibodies correlates with 
moderate protection against malaria in humans74. Unlike humans, mice express 
alpha-gal; when alpha-gal deficient mice are orally treated with Escherichia coli 
O86:B7, which expresses alpha-gal, the mice develop anti-alpha-gal 
antibodies74. While this antibody response did not affect disease severity, it 
inhibited Plasmodium sporozoite transmission, limiting the parasite’s ability to 
reach the liver from its injection site in the skin74. Based on this data, the 
microbiota can provide protection from malaria through cross-reactivity of 
bacterial antigens. 
 Similarly, Plasmodium has been shown to cause intestinal pathology and 
affect the gut microbiota. 10 days after Py nigeriensis infection, there is 
considerable sequestration of pRBCs in the gut microvasculature, with significant 
infiltration of Ly6C+Ly6G- monocytes in the lamina propria along with an increase 
in inflammatory cytokine expression caused by the pRBCs37. During infection, a 
shift was seen in the microbiota composition at day 10 p.i., with an increase in 
Bacteroidetes and a decrease in Firmicutes; however, by day 15 p.i. the majority 
of the observed changes had returned to baseline37. When C57BL/6 mice are 
infected with P. berghei ANKA infection to model cerebral malaria, significant gut 
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pathology occurs, including shortening of the intestines and villi along with 
increased mucus thickness and intestinal permeability38. Along with this 
pathology, the gut microbiota became increasingly different from baseline, with a 
decrease in abundance of the Lactobacillaceae family but increases in 
Enterobacteraceae and Verrucomicrobiaceae38. Overall, Plasmodium infections 
can cause inflammation-related damage to the intestine and modulate the 
composition of the gut microbiota.  
 With the convergence of malaria and the gut microbiota, the goal of this 
dissertation is to characterize interactions between the gut microbiota, the host, 
and Plasmodium using the mouse model of malaria. Additionally, the effect of 
antimalarial drugs on the composition of the gut microbiota is studied.
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CHAPTER 2 
COMPOSITION OF THE GUT MICROBIOTA MODULATES THE SEVERITY OF 
MALARIA1 
 
Plasmodium infections result in clinical presentations that range from 
asymptomatic to severe malaria resulting in approximately one million deaths 
annually. In spite of this, the factors that determine disease severity remain 
poorly understood. Here we show that the gut microbiota of mice influences the 
pathogenesis of malaria. Genetically similar mice from different commercial 
vendors, which exhibited differences in their gut bacterial community, had 
significant differences in parasite burden and mortality after infection with multiple 
Plasmodium species. Germ-free mice that received cecal content transplants 
from ‘resistant’ or ‘susceptible’ mice had low and high parasite burdens, 
respectively, demonstrating the gut microbiota shaped the severity of malaria. 
Among differences in the gut flora were increased abundances of Lactobacillus 
and Bifidobacterium in resistant mice. Susceptible mice treated with antibiotics 
                                                     
1 Villarino, N. F. et al. Composition of the gut microbiota modulates the severity of malaria. Proceedings of 
the National Academy of Sciences of the United States of America 113, 2235-2240, 
doi:10.1073/pnas.1504887113 (2016). 
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followed by yogurt made from these bacterial genera displayed a decreased 
parasite burden. Consistent with differences in parasite burden, resistant mice
exhibited an elevated humoral immune response compared to susceptible mice.
Collectively, these results identify the composition of the gut microbiota as a 
novel risk factor for severe malaria and modulation of the gut microbiota (e.g. 
probiotics) as a potential treatment to decrease parasite burden.
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Introduction 
Plasmodium infections are a global health burden causing over 200 million 
cases of malaria and around one million deaths annually, with the vast majority of 
fatalities being children under the age of 5 living in sub-Saharan Africa75. Many 
Plasmodium infections are either asymptomatic or cause only mild malaria. Yet, 
some infections progress to severe malaria that most often manifest as impaired 
consciousness (cerebral malaria), respiratory distress, and severe anemia3. The 
best correlate of disease severity following P. falciparum infection in humans is 
parasite density76,77. 
The gut microbiota impacts multiple facets of host physiology78 including 
shaping susceptibility to numerous diseases61,79-86. The effects of the gut 
microbiota on the host are strongly influenced by the collective composition of the 
bacterial populations87 and commensal flora are known to affect local pathogen 
burdens and host immunity88-90. In addition to influencing local gut immunity, the 
gut microbiome also affects host immunity to extra-gastrointestinal tract viral 
infections72.  
Recent studies also support that the gut microbiome modulates 
Plasmodium infections in humans. Anti-α-gal antibodies, induced by the gut 
pathobiont E. coli O86:B7, cross-react with sporozoites from human and rodent 
Plasmodium species that impair transmission of the parasite between the vector 
and vertebrate host, however this cross-reactive immunity did not affect blood 
stage parasite burden74. Additionally, the stool bacteria composition of Malian 
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children correlated prospectively with risk of P. falciparum infection, but not 
progression to febrile malaria91. Importantly, it remains unclear whether the gut 
microbiome also contributes to the development of severe malaria. Using a 
murine model of malaria, we demonstrate that the gut microbiome effects blood 
stage parasite burden and the subsequent severity of malaria. 
 
Results 
Mice from Different Vendors Exhibit Differential Susceptibility to Malaria 
Genetically similar inbred strains of mice (C57BL/6) maintained by 
different vendors (Jackson Laboratories and Taconic) have differences in their 
gut bacterial communities92,93. To determine whether these differences had any 
effect on Plasmodium infections C57BL/6 mice from Jackson Laboratories (Jax), 
Taconic (Tac), National Cancer Institute/Charles River (NCI) and Harlan (Har) 
were infected with P. yoelii. Following infection, profound differences in 
parasitemia (the fraction of red blood cells infected with P. yoelii) were observed 
among the four groups of mice (Fig. 2-1A,B). Whereas resistant mice (Jax and 
Tac) exhibited a maximum of approximately 10% parasitemia, they had no signs 
of morbidity (weight loss) or mortality, which was in contrast to the substantial 
weight loss and mortality observed in susceptible mice (NCI and Har) where 
parasitemia was >60% (Fig. 2-1C,D). Moreover, NCI and Har mice exhibited 
more profound and longer lasting anemia (loss of red blood cells (RBCs) per mL) 
compared to Jax and Tac mice (Fig. 2-2A). Additionally, when total number of 
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RBCs per mL was used to derive total pathogen burden we noted similarities 
between the parasite burden as detected by parasitemia or parasitized RBCs 
(pRBCs) per mL of blood (Fig. 2-2B-E). Of note, mice infected with different 
doses of P. yoelii pRBCs showed similar parasitemia kinetics between the 
different doses and susceptibility to infection (Fig. 2-3) suggesting mice from 
different vendors are differentially susceptible to progression to severe malaria 
but not to blood stage infection. 
To determine the broader applicability of these data, another mouse strain 
and two Plasmodium species were tested. BALB/c mice from Jax, Tac, Charles 
River (CR) and Har were infected with P. yoelii. Mice were purchased from CR in 
lieu of NCI/CR. Of note, C57BL/6 mice purchased from CR exhibit similar 
parasitemia and morbidity as NCI mice following infection with P. yoelii (Fig. 2-4). 
Consistent with P. yoelii infections in C57BL/6 mice (Fig. 2-5), BALB/c mice from 
Jax and Tac exhibit reduced P. yoelii parasitemia compared to mice from CR and 
Har (Fig. 2-5A,B). Furthermore, C57BL/6 mice from Jax and Tac exhibited 
reduced parasitemia compared to CR and Har following Plasmodium chabaudi 
infection (Fig. 2-5C,D). Finally, we assessed the development of experimental 
cerebral malaria (ECM) in C57BL/6 mice infected with Plasmodium berghei 
ANKA. Jax and Tac mice trended towards reduced parasitemia compared to NCI 
and Har mice at early time points, moreover there was a significant (p=0.04) 
difference in survival between these groups of mice (Fig. 2-5E,F). Collectively, 
these data indicate the severity of malaria is dependent on the source of mice. 
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Diet is a strong modulator of organismal health as well as of the gut 
microbiome and its function63. To determine whether the diet could shape the 
severity of malaria, Jax and NCI mice were fed one of two commercially available 
rodent diets, either the in-house NIH-31 (used in Fig. 2-1A-D) or Teklad 22/5. 
Parasitemia in NCI mice was unaffected; however, Jax mice had high levels of 
parasitemia when fed Teklad 22/5 (Fig. 2-1E,F). Consistent with the parasitemia 
data, Jax mice fed Teklad 22/5 also exhibited substantial weight loss and 
elevated mortality compared to Jax mice fed NIH-31 (Fig. 2-1G,H). Since these 
diets had no effect on parasite burden in NCI mice, the changes in parasitemia in 
Jax mice were unlikely due to a direct effect of these diets on the parasite 
burden. Moreover, high parasite burdens in NCI mice fed NIH-31, suggest this 
diet supported the proliferative expansion of P. yoelii. When Jax and NCI mice 
were placed on the reciprocal vendor-specific diet and then infected with P. yoelii 
we noted a modest increase in parasite burden in Jax mice fed the NCI in-house 
diet, but no effect of the Jax in-house diet on NCI mice (Fig. 2-6). Collectively, 
these data sets led to the hypothesis that the gut microbiota influenced 
Plasmodium infections. 
 
Gut Bacterial Community Structure and Function are Different in Resistant 
and Susceptible Mice 
To directly test for differences in the gut microbiome, sections of the 
gastrointestinal tract from resistant (Jax and Tac) and susceptible (NCI and Har) 
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mice were collected and the bacterial communities were characterized using 16S 
rRNA gene analysis. There was a high degree of similarity between the microbial 
community assemblages found within the cecum and the colon of mice from the 
same vendor (Fig. 2-7A), while there were clear differences between the 
microbial communities of these regions compared to the distal half of the small 
intestine within the same vendor. Moreover, significant differences between mice 
from all vendors were apparent in the non-metric multidimensional scaling 
(NMDS) analysis of population structure within the cecum, with the susceptible 
NCI and Har libraries showing a comparative overlap with each other yet distinct 
differences when compared to the resistant Jax and Tac communities (Fig. 2-
7B). Analysis of the cecal bacterial communities at the family level revealed 
substantial differences, with Clostridiaceae, Erysipelotrichaceae, 
Lactobacillaceae, and Peptostreptococcaceae (members of the Firmicutes 
phylum) being proportionally more abundant in resistant (Jax and Tac) mice, 
whereas Bacteroidaceae and Prevotellaceae (members of Bacteroidetes 
phylum), and Sutterellaceae (member of Proteobacteria phylum) were 
proportionally more abundant in susceptible (NCI and Har) mice (Fig. 2-8A,B). 
Finally, dietary changes are capable of inducing significant changes in the gut 
microbiome94 that reach steady state within 3-4 days in mice95. Consistent with 
these reports, we observed defined changes in the gut bacterial communities in 
Jax mice fed Teklad 22/5 or NIH-31 (Fig. 2-9, 2-10), with a noted decrease in 
Peptostreptococcaceae in Jax mice fed Teklad shifting closer towards that seen 
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in susceptible NCI and Har mice (Fig. 2-9C). These changes coincide with a shift 
in the severity of malaria between these two groups of mice (Fig. 2-1E-H). 
Consistent with changes in the gut bacterial community, analysis of 
metabolites in the small intestine, cecum, and plasma of Jax and NCI mice 
revealed differential expression between each tissue (Fig. 2-11A). An F-test of 
partial least squared discriminant analysis (PLS-DA)96 used to probe variation 
between metabolite profiles in Jax and NCI mice on a per tissue basis confirmed 
that the means of the variate 1, which differentiated Jax from NCI mice in all 
tissues, were significantly different (p≤0.0003, 0.0001, 0.0001) for the small 
intestine, cecum, and plasma, respectively, (Fig. 2-11B-D, 2-12). Several 
metabolites exhibited large (≥1.5 fold) and statistically significant (p≤0.1) 
differences between Jax and NCI mice, with the top 25% of metabolites 
associated with distinct metabolic pathways (Fig. 2-11E,F). Collectively, 
differences in the gut bacterial populations and metabolites support the 
hypothesis that the severity of malaria is modulated by differences in gut 
bacterial communities. 
 
Differences in the Gut Microbiome Shape Susceptibility to Malaria 
To directly test this hypothesis, genetically identical germ-free (GF) 
C57BL/6 mice received cecal content transplants from either Jax or NCI mice. 
Sequence analyses demonstrated the bacterial communities in colonized germ-
free mice reflected that of the donor communities and were different than the 
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communities in germ-free mice exposed to only environmental microbes (Fig. 2-
13A). Furthermore, there was only a slight decrease in community diversity 
between respective donor and colonized germ-free mice (Fig. 2-14). Following P. 
yoelii infection, germ-free mice that received either Jax or NCI cecal transplants 
had parasite burdens similar to control Jax and NCI mice (Fig. 2-13B,C). Both 
NCI control mice and germ-free mice that received NCI cecal transplants also 
had decreased survival compared to the Jax control mice and germ-free mice 
that received Jax cecal transplants (Fig. 2-13D). Collectively, these data provide 
a direct demonstration that the severity of malaria was modulated by the gut 
microbiota. 
 
Decreased Parasite Burden in Mice Treated with Lactobacillus and 
Bifidobacterium 
To identify individual microbial phylotypes that may shape the severity of 
malaria, a deeper analysis was performed on the bacterial communities in the 
cecum. When pooled by resistance (Jax/Tac) or susceptibility (NCI/Har) to P. 
yoelii, several phylotypes (referred to here as Operational Taxonomic Units, 
OTUs) emerged from a linear discriminant analysis (LDA) effect size (LEfSe)-
driven analysis97 as biomarkers of the resistant or susceptible phenotype. Among 
those differences, Lactobacillus and Bifidobacterium were overly abundant in the 
resistant mice compared to susceptible mice (Fig. 2-15), with differences in 
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Lactobacillus being the greatest driver of the differential community structure 
between resistant and susceptible mice (Fig. 2-15B).  
To evaluate the linkage between Lactobacillus and Bifidobacterium towards 
resistance to severe malaria, Jax and NCI mice were treated with lab-cultured 
yogurt supplemented with probiotics that contained Lactobacillus and 
Bifidobacterium species prior to and following infection with P. yoelii. DNA 
sequencing of Lactobacillus isolated from fecal pellets from Jax and NCI mice or 
lab-cultured yogurt demonstrated phylogenetic congruence (Fig. 2-16). 
Consumption of Lactobacillus and Bifidobacterium can modulate the gut 
microbial community structure98 or function99. Following infection with P. yoelii, 
both Jax and NCI mice treated with yogurt had a modest, but significant (Jax 
p<0.0001; NCI p=0.0418), decrease in parasite burden compared to control 
untreated mice (Fig. 2-17). Jax and NCI mice treated with milk used to make the 
yogurt showed a similar parasite burden as control Jax and NCI mice (mean 
AUCDay 5-34: Jax control (n=4) 107.2±11.39 (S.D.) versus Jax milk (n=4) 
83.55±24.83 (S.D.) p = 0.13; NCI control (n=4) 447.1±85.65 (S.D.) versus NCI 
milk (n=3) 384.8±73.08 (S.D.) p = 0.36). However, when mice were treated with 
antibiotics prior to yogurt treatment we observed a profound decrease in parasite 
burden in the susceptible NCI mice (Fig. 2-18A,B), and no weight loss in those 
mice compared to the other NCI groups (Fig. 2-18C). Whereas other constituents 
of the gut microbiota may contribute to regulating the severity of malaria, these 
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data support the ability of Lactobacillus and Bifidobacterium to contribute towards 
the modulation of Plasmodium parasite burden. 
 
Severity of Malaria Tracks with the Magnitude of the Host Immune 
Response 
The gut microbiota can shape host immunity to systemic viral infections72 
and T follicular helper (Tfh) produced IL-21 is required for GC B cell help and 
clearance of murine Plasmodium infections44. Consistent with these 
observations, resistant Jax mice exhibited an elevated P. yoelii-specific CD4+ T 
cell (CD49dhiCD11ahi, Tfh cell, and GC B cell responses compared to susceptible 
NCI mice (Fig. 2-19A-C; Fig. 2-20)51. Jax and NCI mice had similar titers of IgM 
specific for the 19-kDa fragment of merozoite surface protein 1 (MSP119) from P. 
yoelii (Fig. 2-19D), suggesting similar activation of B cell in both groups. In 
contrast, Jax mice exhibited accelerated antibody class switching from MSP119-
specific IgM to IgG isotypes compared to NCI mice (Fig. 2-19D). These results 
support the possibility that the gut microbiome modulates the severity of malaria 
following P. yoelii infection through modulation of the host immune response. 
 
Discussion 
This study demonstrates that the murine gut microbiome influences the 
parasite burden of Plasmodium rodent species and modulates the severity of 
malaria in mice. Importantly, parasite burden is currently the best-known 
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correlate of disease severity following P. falciparum infection in humans76,77. An 
association between the gut microbial community and Plasmodium parasites has 
been previously recognized in the mosquito vector100-104. Interestingly, the unique 
assemblage of skin bacteria on human skin has also been shown to impact the 
attractiveness of Anopheles mosquitoes to particular individuals105,106. 
Two recent publications also support that the gut microbiota affects 
mammalian stages of the Plasmodium life cycle. The first study demonstrated 
that specific gut bacteria could impact the transmission of P. berghei sporozoites 
from mosquitos to mice74. The authors showed that the gut pathobiont, 
E. coli O86:B7, induced the production of anti-α-gal antibodies. When 
Plasmodium-infected mosquitoes injected sporozoites into the dermal tissue 
during a blood meal the anti-α-gal antibodies bound to the Plasmodium 
sporozoites, which prevented their migration to the liver74. These results also 
extended to humans where the presence of anti-α-gal IgM antibodies correlated 
with protection against P. falciparum infection. The effect of E. coli O86:B7 on 
Plasmodium infection was limited to transmission of sporozoites as there was no 
effect of the anti-α-gal antibodies on the symptomatic blood stage of the 
infection. Consistent with these findings a second report demonstrated that the 
unique composition of stool bacteria in Malian children correlated with 
prospective risk of P. falciparum infection, although not progression to febrile 
malaria91. Although the mechanism responsible for this observation is unknown, 
the similarities between these two studies (i.e., susceptibility to infection but not 
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severity of blood stage infection) suggest the prospective risk of P. falciparum 
infection differentiated by stool bacteria composition may be attributed to 
differences in anti-α-gal IgM antibodies. In contrast to these two publications, we 
show that the gut microbiota modulates the severity of P. yoelii blood stage 
infections in mice, implying a novel and independent mechanism. Moreover, our 
findings show that the influence of the gut microbiome on Plasmodium infections 
is broad and not limited to the transmission of the parasite. Taken together our 
observation and those of Yilmaz et al.74, result in the intriguing speculation that 
the human intestinal microbiota might impact different stages of the Plasmodium 
life cycle in humans. Clearly, this is an area ripe for future research.  
One potential mechanism by which the gut microbiota regulates the 
severity of malaria is a direct effect on the parasite itself where gut microbiota-
derived products either promote or inhibit its growth. Whereas this possibility has 
not been formally excluded, we observe similar parasitemia expansion kinetics, 
when plotted on a log-scale, between days 5 and 11 post-infection in both 
resistant and susceptible mice. This observation suggests that the gut microbiota 
does not have a direct effect on the parasite. Consequently, it is more likely that 
the gut microbiota impacts the severity of malaria by modulating the host immune 
response to Plasmodium. Consistent with this possibility, resistant Jax mice 
exhibited an elevated anti-Plasmodium immune response compared to 
susceptible NCI mice. While these exciting data correlate with the parasite 
burden in these mice further experiments will be necessary to demonstrate the 
  29
differential immune response is responsible for the difference in severity, and if 
so, how the gut microbiota modulates the host immune response to this extra-
gastrointestinal infection. It has been previously shown that the gut microbiome 
provides signals to monocytes/macrophages that primed those cells to respond 
to and help control systemic LCMV infections72. Whether the gut microbiome 
modulates host immunity to Plasmodium through similar or different effects on 
the host immune system remains to be determined. 
As mentioned above, diet has a major role in shaping the composition and 
activity of the gut microbiota94,107,108. Consequently, manipulating the structure 
and function of these complex communities through the diet provides an 
excellent opportunity to manipulate the host immune system107. In our study, we 
identified that Lactobacillus and Bifidobacterium species in cecal content could 
have a protective role by modulating the parasite burden and attenuating the 
severity of the disease. On the other hand, it is possible that these bacterial 
genera correlate with decreased parasitemia through niche competition that 
decreases the abundance of bacterial genera that cause elevated parasitemia. 
Since antibiotic treatment followed by yogurt treatment triggered a 14-fold 
reduction in parasite burden in susceptible mice, these exciting results suggest 
that through optimization (e.g., identifying and treating with the most effective 
‘protective’ bacterial species or eliminating bacteria that contribute to high 
parasitemia) modulating the gut microbiome has the potential be a novel 
prophylaxis to prevent severe malaria. Consistent with this possibility, prior work 
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has shown that children in a rural African village in Burkina Faso have an 
enrichment of the Bacteroidetes phylum and a depletion of the Firmicutes 
phylum, which contains Lactobacillus, compared to European children109. This 
resembles the community structure in susceptible mice that have increased 
Bacteroidetes and reduced Firmicutes compared to resistant mice (Fig. 2-15). 
Therefore, the commonality between the bacterial community structure in African 
children and Plasmodium susceptible mice suggests the possibility that probiotic 
modulation of the gut microbiota in mice to control severe malaria might work in 
humans.  
This report demonstrates the novel observation that the severity of malaria 
in mice is profoundly impacted by the composition of the gut microbiota. The data 
lead to the hypothesis that differences in the gut microbiota may explain why 
some humans infected with Plasmodium progress to severe disease while others 
do not. The results also support the possibility that manipulating the gut 
microbiota has the potential to control the severity of malaria in humans. 
Whereas modulating the gut microbiota may not prevent Plasmodium infections, 
altering the gut microbiome has the potential to ameliorate severe disease and 
save hundreds of thousands of lives annually. 
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Materials and Methods 
Animals and Housing 
Conventionally housed mice: Female C57BL/6J and BALB/cJ mice (6-8 weeks 
old) were purchased from The Jackson Laboratory (Bar Harbor, Maine); 
C57BL/6N and BALB/cN mice (6-8 weeks old) were purchased from the National 
Cancer Institute (Frederick, MD), Charles River Laboratories 
(Wilmington, MD), Harlan Laboratories (Indianapolis, IN) and Taconic (Hudson, 
NY). Mice were acclimatized for a minimum of 7 days prior to starting 
experiments.  
Germ–free mice: Female C57BL/6J mice (8-10 weeks old) were purchased from 
The National Gnotobiotic Rodent Resource Center at the University of North 
Carolina-Chapel Hill. Upon arrival at the University of Tennessee the mice were 
kept in the transporting box until fecal transplant was done, then mice were 
housed in conventional (specific pathogen free) conditions. Animal experiments 
were carried out at The University of Tennessee adhering to the local and 
national regulations of laboratory animal welfare. Procedures involving the care 
or use of mice were reviewed and approved by The University of Tennessee 
Institutional Animal Care and Use Committee. 
Diets: Unless noted otherwise mice were fed NIH-31 Modified Open Formula 
Mouse/Rat Irradiated Diet (Harlan 7913) (Harlan, Indianapolis, IN). In some 
experiments mice were fed Teklad 22/5 Rodent Diet (Harlan 8640; Harlan, 
Indianapolis, IN), Jackson Laboratory in-house diet (5K67; Cincinnati Lab & Pet 
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Supply, Inc.; Cincinnati, OH) or NCI/CR in-house diet (5L79 Cincinnati Lab & Pet 
Supply, Inc.; Cincinnati, OH). Mice were placed on the respective diets upon 
arrival at the facility and maintained on the different diets for at least one week 




Mice were infected with P. yoelii 17XNL, P. chabaudi AS, or P. berghei 
ANKA. For P. yoelii or P. berghei ANKA infections mice received 1x105 
parasitized red blood cells (intravenously) prepared from frozen/thawed stabilites. 
For P. chabaudi infections, experimental mice were infected intraperitoneally with 
freshly prepared 1x105 parasitized red blood cells after one in vivo passage in 
C57BL/6 mice.  
 
Evaluation of Parasitemia 
Blood samples were taken from the tail at regular intervals from 3 to 35 
days post-infection. Parasitemia was assessed by evaluation of thin blood 
smears or flow cytometry. Thin blood smears–at least 5 high-power (1000x) 
fields were assessed for each sample. Total red blood cells and parasitized red 
blood cells were counted in each field. Flow cytometry–about 5-10 μl of blood 
was added to PBS and then fixed with 0.00625% gluteraldehyde. Cells were 
stained with CD45.2-APC (clone 104; Biolegend; San Diego, CA), Ter119-
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APC/Cy7 (clone TER-119; Biolegend; San Diego, CA), dihydroethidium (Sigma 
Aldrich; St. Louis, MO), and Hoechst 33342 (Sigma Aldrich; St. Louis, MO). Red 
blood cells (CD45.2- Ter119+) were gated on and Plasmodium infected cells 
were subsequently identified as dihydroethium+ Hoechst 33342+. Parasitemia 
represents the percentage of red blood cells infected with P. yoelii, P. chabaudi 
or P. berghei.  
  
Enumeration of Red Blood Cells and Parasitized Red Blood Cells 
Blood samples were collected and used to quantify red blood cells per mL 
using a hemocytometer, and percent parasitemia. Red blood cells per mL and 
percent parasitemia were used to calculate the number of parasitized red blood 
cells per mL of blood.  
 
Cecum Transplant 
Cecal content was squeezed from donor mice (n=3-5 mice per group) into 
a sterile petri dish. Immediately after harvesting the cecum material, it was 
diluted with sterile saline (2 mL) and mixed gently for ~30 seconds. Each germ-
free mouse received the diluted cecum material (200 μL/mouse) administered by 
oral gavage. For each mouse, a new sterile oral gavage needle was used. After 
the cecal transplant, mice were housed using conventional conditions. Mice were 
infected with P. yoelii 3 weeks after the cecal transplant.  
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Gut Microbiota Analysis  
Tissue collection: The distal half of the small intestine, cecum, and colon  
were excised from mice and flash frozen in liquid nitrogen. Samples were then 
stored at -80°C.  
DNA isolation: DNA was extracted from samples using the MoBio PowerSoil 
DNA Isolation Kit (MoBio Laboratories Inc., Carlsbad, CA) according to 
manufacturer’s protocols. No effort was made to separate mouse tissue from the 
bacterial component so as not to select against bacteria that were in close 
association with mouse tissue.  
Ribosomal 16S sequencing: For amplification of bacterial 16S rRNA genes, 
bacteria-specific PCR primers targeting the V4 region (bases 515-806) were 
used. Amplification, barcoding and sequencing were completed by the Genome 
Sequencing Center at the Hudson-Alpha Institute for Biotechnology (Huntsville, 
AL) using the MiSeq platform with 150 bp paired-end reads.  
Community analysis: We used the Mothur software package (version 1.33.1)110 
to process sequences of sufficient length and quality similarly to the Schloss 
MiSeq SOP (http://www.mothur.org/wiki/MiSeq_SOP). Mothur was also used to 
cluster sequences into phylotypes and for phylogenetic classification and to sort 
our sequences into groups based on the region of the digestive tract from which 
the DNA was extracted. The Primer-E software package (Version 6)111 was used 
to interrogate the relationships between phylotypes across samples and to derive 
correlations between phylotype presence/abundance and other parameters. The 
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“.shared” file (a matrix file containing phylotype abundances for each sample), 
created by Mothur, was imported directly into the Primer-E software package. All 
phylotype abundances were standardized to the total number of sequences per 
barcoded library (proportional abundances). Standardized abundances were 
square-root transformed to partially deemphasize more highly abundant 
phylotypes. A Bray-Curtis similarity matrix was constructed and used to perform 
non-metric multidimensional scaling analysis (NMDS) for visualization of 
community structure relationships between the different samples. Detection of 




Collection of small intestine and cecum content samples: Immediately after 
euthanasia, the abdominal cavity was exposed and the small intestine and the 
cecum were dissected from the other intestinal sections. The small intestine and 
cecum contents were collected into petri dishes by squeezing the tissues from 
the proximal to distal ends of the organs. In addition, extraction solvent (1mL) 
(40:40:20 HPLC grade methanol, acetonitrile, water with 0.1% formic acid) was 
used to flush the small intestine and the cecum using a needle and syringe. The 
intestine contents were then transferred into separate cryotubes and flash frozen 
in liquid nitrogen. The samples were kept on ice for approximately one hour until 
extraction. 
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Collection of plasma samples: Blood was collected from the peri-orbital sinus 
using heparinized capillary tubes under general anesthesia with isoflurane. 
Immediately after collection, blood samples were transferred to centrifuge tubes 
and centrifuged for 10 minutes at 2,000 x g at room temperature. Following 
centrifugation, plasma samples were transferred to cryotubes and flash frozen in 
liquid nitrogen. The samples were kept on ice for approximately one hour until 
extraction.  
Sample extraction and analysis: Extraction of samples was allowed to proceed at 
-78°C for 20 minutes. Samples were then centrifuged for 5 minutes (16.1 rcf) at 
4°C. The supernatant was transferred to new vials and the sample pellet was 
resuspended in 200 μL of chilled (4°C) extraction solvent. The extraction was 
allowed to proceed for 15 min at -20°C at which time the samples were 
centrifuged for 5 min (16.1 rcf) at 4°C. The supernatant was transferred to vials 
and another 50 μL of extraction solvent was added to the sample pellet where 
the extraction was repeated once more. Vials containing all of the collected 
supernatant were dried under a stream of N2 until the extraction solvent had 
evaporated. Solid residue was resuspended in 300 μL of sterile water and 
transferred to autosampler vials. Samples were immediately placed in 
autosampler trays for mass spectrometric analysis. 
Ultra-Performance Liquid Chromatograpy—High Resolution Mass Spectrometric 
(UPLC-MS) Analysis: Samples were placed in autosampler trays and kept at 
4°C. A 10 μL aliquot of each was injected through a Synergi 2.5 micron Hydro-
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RP 100, 100 x 2.00 mm LC column (Phenomenex) kept at 25°C. The eluent was 
introduced into the MS via an electrospray ionization source conjoined to a 
Thermo Scientific Exactive Plus Orbitrap MS through a 0.1 mm internal diameter 
fused silica capillary tube, and the MS was run in fullscan mode with negative 
mode ionization using a method adapted from Rabinowitz112. Briefly, the samples 
were run with a spray voltage was 3 kV. The nitrogen sheath gas was set to a 
flow rate of 10 psi with a capillary temperature of 320°C. AGC target was set to 
3e6. The samples were analyzed with a resolution of 140,000 and a scan window 
of 85 to 800 m/z for from 0 to 9 minutes and 110 to 1000 m/z from 9 to 25 
minutes. Solvent A consisted of 97:3 water:methanol, 10 mM tributylamine, and 
15 mM acetic acid. Solvent B was methanol. The gradient from 0 to 5 minutes 
was 0% B, from 5 to 13 minutes was 20% B, from 13 to 15.5 minutes was 55% 
B, from 15.5 to 19 minutes was 95% B, and from 19 to 25 minutes was 0% B with 
a flow rate of 200 μL/min.  
Metabolite feature extraction and data processing: The RAW files generated by 
the instrumental data collection software Xcalibur (Thermo Scientific) were 
converted to the mzML format113 using the ProteoWizard package114. The 
MAVEN software package (Princeton University) was used to automatically align 
the total ion chromatograms using the retention times of annotated metabolites 
and other dominant features from each sample115,116. Metabolites were manually 
identified and integrated using known masses (± 5 ppm mass tolerance) and 
retention times (Δ≤1.5 min). Metabolite ion counts were normalized via mass for 
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cecum and small intestine samples, and fold changes were calculated between 
samples. The resulting data were clustered using Cluster 3.0117 and heatmaps 
were then generated from clustered data using Java Treeview118 software. PCA 
analyses were performed and figures were generated using the statistical 
package R along with the ggplot2119 and ggbiplot120 packages. PLS-DA plots 
were also generated via R along with the mixOmics121 package using metabolite 
areas as the predictors and mouse type as the discrete outcomes with a 
tolerance of 1 x 10-6 and a max iteration of 500.  
 
Yogurt treatment 
Antibiotic treated mice were treated orally with an antibiotic cocktail 
consisting of ampicillin (0.5 mg/ml) (Sigma Aldrich; St. Louis, MO), vancomycin 
(0.25 mg/ml) (Amnesco; Solon, OH), metronidazole (0.5 mg/ml) (Spectrum 
Chemical Mfg. Comp.; Gardena, CA), neomycin sulfate (0.5 mg/ml) (EMD 
Millipore; Billerica, MA), and gentamycin sulfate (0.5 mg/ml) (Corning; Manassas, 
VA). Mice were treated ad libitum for 3 weeks. Water bottles containing the 
antibiotic cocktail were changed weekly. After 3 weeks antibiotic treatment 
ceased and half of the antibiotic treated mice were then treated with yogurt for 3 
weeks prior to the P. yoelii infection. Yogurt was made using a starter culture 
containing Lactobacillus bulgaricus, L. acidophilus, L. lactis, Bifidobacterium 
lactis, and Streptococcus thermophilus (Yogurt Starter Culture #2, Custom 
Probiotics, Glendale, CA). In addition, yogurt was enriched with a probiotic 8 
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powder supplement containing L. acidophilus, L. rhamnosus, L. salivarius, L. 
plantarum, L. casei, L. lactis, B. breve, B. infantis, B. longum, B. bifidum, and B. 
lactis (11 Strain Probiotic Powder, Custom Probiotics, Glendale, CA). Fresh 
yogurt was made for each treatment by adding the starter culture (1.2 grams) 
and the probiotic supplement (1.2 grams) to 15 mL of 2% reduced fat milk 
(Mayfield, Athens, TN) or organic 2% reduced fat milk–antibiotic pretreatment 
experiment (Organic Valley; La Farge, WI). The yogurt was then incubated at 
37°C for 6-8 hours before administration. Mice were treated with yogurt as 
described in figure legends with 0.2 ml administered by oral gavage.  
 
Isolation and Sequencing of Lactobacillus  
Fecal pellets from Jackson and NCI mice were processed separately. 
Pellets were homogenized in buffered saline solution and plated onto 
Lactobacillus-selective MRS agar. Plates were subsequently incubated at 37°C 
in anaerobic culture jars. Single colonies were re-streaked three times to purify 
the strains. DNA was extracted from bacterial colonies, lab-cultured yogurt, and 
probiotic powder using the MoBio Powersoil DNA extraction kit (MoBio, Carlsbad, 
CA) according to the manufacturer’s protocols. An approximately 1500 bp 
segment of the 16S rRNA gene was amplified from isolate DNA, via PCR, using 
the 9F-1522R primer set. PCR products were purified using the Qiaquick PCR 
purification kit (Qiagen, Valencia, CA) and sequenced at the University of 
Tennessee Molecular Biology Resource Facility using Sanger sequencing.  
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Cellular Immune Response 
Spleens were disrupted to generate single-cell suspensions in Hyclone 
RPMI 1640 media (Thermo Fisher Scientific Inc., Waltham, MA) supplemented 
with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Inc., Lawrenceville, GA). 
RPMI 1640 was also supplemented with 1.19 mg/ml HEPES (Thermo Fisher 
Scientific Inc., Waltham, MA), 0.2 mg/ml L-glutamine (Research Products 
International Corp., Mt. Prospect, IL), (0.05 units/ml & 0.05 mg/ml) 
penicillin/streptomycin (Invitrogen, Grand Island, NY), 0.05 mg/ml gentamicin 
sulfate (Invitrogen, Grand Island, NY), and 0.05 μM 2-Mercaptoethanol (Thermo 
Fisher Scientific Inc., Waltham, MA). Single cell suspensions were treated with 
ammonium chloride potassium to lyse red blood cells. Spleens were harvested 
as indicated at the number of days post infection. Cells were stained with Fc 
block (anti-CD16/32; clone 2.4G2) and the following fluorescence-conjugated 
antibodies (CD45.2; clone 104, CD4; clone RM4-5, CD8; clone 53-6.7, CD3; 
clone 17A2, CD19; clone 6D5, Ter119; clone Ter-119, CD11a; clone M17/4, 
CD49d; clone R1-2, PD-1; clone 29F.1A12, CD95; clone Jo2, GL7; clone GL7, 
biotion-CXCR5; clone 2G8, CD44; clone IM7) purchased from Biolegend (San 
Diego, CA) and BD Biosciences (San Diego, CA). For CXCR5 staining cells were 
stained with biotinylated-CXCR5 for 30 minutes at room temperature prior to 
staining with fluorescence-conjugated streptavidin. Antibodies were resuspended 
in FACS buffer (1x PBS, 1% FBS, 0.02% sodium azide) and cells were stained 
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for 30 minutes at 4°C. Following staining cells were fixed and permeabilized with 
Fixation Buffer (Biolegend, San Diego, California). Cells were acquired through 
an LSR II (BD Biosciences). Data were analyzed by FlowJo software (Tree Star, 
Ashland, OR).  
 
Detection of P. yoelii MSP119-specific Antibodies 
Serum was collected on the indicated days post-P. yoelii infection and 
stored at -20°C. MaxiSorp Immuno plates (Thermo Scientific) were coated with 1 
μg/ml recombinant MSP119 (The following reagent was obtained through the 
MR4 as part of the BEI Resources Repository, NIAID, NIH: Plasmodium yoelii 
yP.y.MSP1-19(XL)/VQ1, MRA-48, deposited by DC Kaslow.) Dilutions of serum 
were added to wells. Total MSP119-specific IgM, IgG1, IgG2b, IgG2c, and IgG3 
antibodies were detected with horseradish peroxidase–conjugated goat anti–
mouse IgM, IgG1, IgG2b, IgG2c, and IgG3, respectively, (Jackson 
ImmunoResearch) and 3,3′,5,5′-tetramethylbenzidine substrate (Arcos 
Organics). Reactions were stopped by addition of 2M H2SO4. Results are 
presented as average endpoint titers with absorbance readings below 0.1 
(absorbance at 450 nm). 
 
Statistical Analysis 
Descriptive and comparative statistical analyses of data, except the gut 
microbiota and metabolomics data, were done using GraphPad Software version 
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6 (La Jolla, CA, USA). The area under the parasitemia curve (AUC) was 
estimated for each group following the trapezoidal rule with the following 
equation122,123: 
AUCt1-t-last =0.5 Σ (Yi + Yi+1) * (ti+1-t i) 
where “t” was sampling time and “y” the observed outcome (e.g., %parasitemia). 
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Figures and Figure Legends 
 
Figure 2-1. Plasmodium parasite burden, morbidity and mortality vary by 
mouse vendor and diet. C57BL/6 mice were infected with P. yoelii parasitized 
  44 
red blood cells. A. Fraction of red blood cells infected with P. yoelii 
(%parasitemia). B. Area under the parasitemia curve (AUC) analysis. Data were 
analyzed by one-way ANOVA and Tukey’s multiple comparison post-test. C. 
Percent weight loss following infection. Data were analyzed by one-way ANOVA. 
D. Survival of mice following infection. Survival curves were analyzed by Log-
rank (Mantel-Cox) test. E-H. Mice were fed either NIH-31 or Teklad 22/5 diets 
before and after P. yoelii infection. E. Percent parasitemia following P. yoelii 
infection. F. AUC analysis. Data were analyzed by one-way ANOVA and Tukey’s 
multiple comparison post-test. G. Percent weight loss following infection. Data 
were analyzed by one-way ANOVA. H. Survival of mice following infection. 
Survival curves were analyzed by Log-rank (Mantel-Cox) test. A-F, H. Data 
(mean±S.E.) are cumulative results (n=8-10 mice/group) from two experiments. 
G. Data (mean±S.D.) are from 4-5 mice per group from one experiment. * p < 
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, n.s. = not significant. 
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Figure 2-2. Differential anemia and circulating parasitized red blood cells 
between mice from different vendors. C57BL/6 mice were infected with 1x105 
P. yoelii parasitized red blood cells. A. Number of red blood cells (RBCs) per mL 
of blood. B. Fraction of red blood cells infected with P. yoelii (%parasitemia). C. 
Percent parasitemia AUC analysis. D. Number of parasitized red blood cells 
(pRBCs) per mL of blood. E. pRBCs/mL of blood AUC analysis. A-E. Data 
(mean±S.E.) are from 3-4 mice/group. A, C, and E. Data were analyzed by one-
way ANOVA and Tukey’s multiple comparison post-test. * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001, n.s. = not significant. 
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Figure 2-3. Similar susceptibility to parasitized red blood cell infection 
between C57BL/6 mice from different vendors. C57BL/6 mice from the 
indicated vendors were infected with the indicated number of P. yoelii parasitized 
red blood cells (pRBCs). A. Fraction of RBCs infected with P. yoelii 
(%parasitemia). Each line represents parasitemia kinetics from an individual 
mouse (n=4 mice/dose/vendor). Data are representative of two experiments. B. 
Number of mice from each vendor infected with the indicated dose of pRBCs and 
the total number of mice injected. Data are cumulative results from two 
experiments. Susceptibility to infection at the different doses between vendors 
was analyzed by two-tailed Fisher’s Exact Test. 
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Figure 2-4. C57BL/6 mice from Charles River are susceptible to high P. 
yoelii parasite burden. C57BL/6 mice were infected with 1x105 P. yoelii 
parasitized red blood cells. A. Fraction of red blood cells infected with P. yoelii 
(%parasitemia). B. Area under the parasitemia curve (AUC) analysis. Data were 
analyzed by one-way ANOVA and Tukey’s multiple comparison test. C. Percent 
weight loss following infection. Data were analyzed by one-way ANOVA. A-C. 
Data (mean±S.E.) are from 3-5 mice/group and representative of two 
experiments. * p < 0.05, *** p < 0.001, n.s. = not significant. 
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Figure 2-5. Modulation of malaria pathogenesis by the gut microbiota is 
generalizable to another mouse strain and Plasmodium species. A-B. 
BALB/c mice were infected with 1x105 P. yoelii parasitized red blood cells. A. 
Fraction of red blood cells infected with P. yoelii (%parasitemia). B. Area under 
the parasitemia curve (AUC) analysis. Data were analyzed by one-way ANOVA 
and Tukey’s multiple comparison test. A-B. Data (mean±S.E.) are cumulative 
results (n=8 mice/group) from two experiments. C-D. C57BL/6 mice were 
infected with 1x105 P. chabaudi parasitized red blood cells. C. Fraction of red 
blood cells infected with P. chabaudi (%parasitemia). D. Area under the 
parasitemia curve (AUC) analysis. Data were analyzed by one-way ANOVA and 
Tukey’s multiple comparison test. C-D. Data (mean±S.E.) are from 3-4 
mice/group and representative of two experiments. E-F. C57BL/6 mice were 
infected with 1x105 P. berghei ANKA parasitized red blood cells. E. Fraction of 
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red blood cells infected with P. berghei (%parasitemia) from surviving mice. Data 
(mean±S.E.) are cumulative results (n=10 mice/group) from two experiments. F. 
Survival of mice following infection (n=10 mice/group). Survival curves were 




Figure 2-6. Inversion of Jax and NCI in-house diets minimally effects 
severity of P. yoelii infection. C57BL/6 mice were placed on one of three 
different rodent chows; NIH-31, Jax in-house diet, or NCI in-house diet, for one-
week prior to infection through resolution of infection. Mice were infected with 
1x105 P. yoelii parasitized red blood cells. A. Fraction of red blood cells infected 
with P. yoelii (%parasitemia). B. Area under the parasitemia curve (AUC) 
analysis. A-B. Data (mean±S.E.) are from 3-4 mice/group and representative of 
two experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, n.s. = not 
significant. C. Survival of mice following infection (n=7-8 mice/group) from two 
experiments. Survival curves were analyzed by Log-rank (Mantel-Cox) test. 




Figure 2-7. Susceptibility to malaria correlates with differences in the gut 
microbial community structure. Bacterial population analysis was performed 
using nonmetric multidimensional scaling analysis. The closer together two 
points are the more similar the libraries are to one another. Libraries with 
similarities greater than 20%, 40%, 60% or 80% are encircled with green, blue, 
teal or red dotted lines, respectively. Triangle=distal portion of the small intestine 
(DSI); Square=cecum; Diamond=colon. A. Analysis of all three regions of the 
digestive tract. B. Analysis of only the cecum bacterial populations. C. 
Percentage of 16S rRNA gene reads of bacterial families comprising at least 
0.01% of reads from at least 1 sample. Abundances of 16S reads at the Family 
level were first normalized to proportional abundances and then the average 
proportional abundance (n=6) for each family was calculated for mice from each 





Figure 2-8. Susceptibility to malaria correlates with differences in cecal 
bacteria populations. A. Bacterial families that were identified as being 
significantly enriched in Jackson or Taconic mice. B. Bacterial families identified 
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as being significantly enriched in NCI or Harlan mice. A-B. Data (mean±S.E.) are 
from 6 mice per group and extracted from analysis in Fig. 2-11c. Data were 
analyzed by Kruskal-Wallis test. 
 
Figure 2-9. Jackson mice fed Teklad 22/5 diet exhibit defined changes in 
cecal bacterial populations. All mice were fed NIH-31, except one group of 
Jackson mice that received Teklad 22/5 (Jax-Tek). A. Cecal bacterial population 
analysis was performed using NMDS. The closer together two points are the 
more similar the libraries are to one another. Libraries with similarities greater 
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than 20%, 40%, 60% or 80% are encircled with green, blue, teal or red dotted 
lines, respectively. Analysis of cecal bacterial populations. Each symbol 
represents an individual mouse. B. Percentage of 16S rRNA gene reads of 
bacterial families comprising at least 0.01% of reads from at least 1 sample. 
Abundances of 16S reads at the Family level were first normalized to 
proportional abundances and then the average proportional abundance (n=6) for 
each family was calculated for mice from each of the groups. C. Bacterial families 
that were identified as being significantly enriched in Jackson or Taconic mice. D. 
Bacterial families identified as being significantly enriched in NCI or Harlan mice. 
C-D. Data (mean±S.E.) are from 6 mice per group and extracted from analysis in 
panel B. Data were analyzed by Kruskal-Wallis test. 
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Figure 2-10. Distinct bacterial community structure in Jackson mice fed 
separate diets. C57BL/6 mice from Jackson Laboratory (Jax) were fed two 
separate diets (NIH-31 (n=6) or Teklad 22/5 (n=6)) for one to three weeks prior to 
removal of gut contents and analysis of gut bacterial community. A. NMDS plot 
displaying the similarity between bacterial populations within the cecum of mice 
fed the different diets. Each symbol represents a single mouse. The closer 
together two points are in the figure, the more similar the libraries are to one 
another. Libraries with similarities greater than 40%, 60% or 80% are encircled 
with blue, teal or red dashed lines, respectively. Selected vectors (lettered A-U), 
overlaid on the figure, were taken from a PCA plot made from all phylotype 
abundances in this study after identification by LEfSe analysis as having 
statistically significant differential abundances in mice fed different diets. B. 
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LEfSe output highlighting differentially abundant phylotypes between Jax mice 
fed the two separate diets. Some of these phylotypes are included in A. as 
vectors. 
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Figure 2-11. Changes in the gut microbial community structure correlate 
with changes in the gut and plasma metabolome in resistant and 
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susceptible mice. A. Principal component analysis of metabolite profiles for all 
sample types. Ellipses size indicates 95% normal probability. Triangle=small 
intestine, square=cecum, circle=plasma. Each symbol represents an individual 
mouse. B-D. Partial least squares discriminant analysis within individual samples 
types: small intestine, cecum, and plasma, respectively. Separation between 
points indicates relative amount of variability. E. Color intensity indicates 
magnitude of the fold change with red being an increase and blue being a 
decrease in metabolite concentrations of Jax with respect to NCI mice. Asterisks 
in parentheses next to metabolite names indicate significance for the change for 
the corresponding row and column. *** p ≤ 0.01, ** p ≤ 0.05, * p ≤ 0.10, (–) not 
significant. F. Metabolites grouped according to metabolic pathways that were 
major drivers in the differentiation of resistant and susceptible mice using PLS-
DA. Data are expressed as a ratio of Jax/NCI with red shades representing 
metabolites higher in Jax mice and blue shades representing metabolites higher 
in NCI mice. (*) = Metabolite that was a driving factor in differentiating resistant 
and susceptible mice, respective to column order. (–) = Metabolite that was not a 
driving factor in variation for the respective column. 
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Figure 2-12. Variability in each sample type for PLS-DA. For each sample 
type, the intra condition distance between the extreme values in each dimension 
are listed. Comparison is also shown for the distance between the average of the 
points for each condition in each dimension. Additionally, the p values are shown 
for the inter conditional comparison. Results show a high level of significance 
between the Jax and NCI samples in the variate 1 dimension. 
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Figure 2-13. Gut microbiome shapes susceptibility to severe malaria. Germ-
free mice were colonized with cecal contents from Jax or NCI mice. A. Bacterial 
population analysis was performed using NMDS, as described in Fig. 2-11. B-D. 
Colonized germ-free mice and control Jax and NCI mice were infected with P. 
yoelii. B. Percent parasitemia following P. yoelii infection. C. AUC analysis. B-C. 
Data (mean±S.E.) from 4-5 mice/group are representative of two experiments. 
Data were analyzed by one-way ANOVA and Tukey’s multiple comparison post-
test. D. Survival of mice following infection. Data are cumulative results (n=8-10 
mice/group) from two experiments. Survival curves were analyzed by Log-rank 




Figure 2-14. Germ-free mice colonized with cecal content have similar 
bacterial diversity as donor sample. Germ-free mice were colonized with cecal 
contents from Jax or NCI mice.The 1-λ (Simpson Index) was calculated for 5 
different mouse types (Jax-Donors (n=4), GF-Jax recipients post-cecal transplant 
(n=5), NCI Donors (n=3), GF-NCI recipients post-cecal transplant (n=5) and GF 
mice receiving no transplant (n=5)). Data are mean±SD. Communities with 
values closer to 1 are considered to be more diverse. 
 
  62 
 
Figure 2-15. Lactobacillus and Bifidobacterium are among the bacteria that 
drive differences between the gut-associated bacterial communities of 
resistant and susceptible mice. A. LEfSe cladogram illustrating all 313 
phylotypes in this study. Red identifies phylotype biomarkers for resistance to 
malaria and green identifies phylotype biomarkers for susceptibility to malaria. 
Circle size reflects the sequence abundance within the samples. B. Top ten 
phylotypes with largest effect sizes for susceptibility and resistance to malaria. 
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Figure 2-16. Phylogenetic tree of bacteria isolated from stool samples and 
lab-cultured yogurt. A maximum likelihood tree was constructed from an 
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alignment of 16S rRNA gene sequences approximately 573 base pairs long. 
Sequences used to construct the tree were obtained from bacterial isolates 
(cultured from Jackson and NCI mouse fecal pellets) and from PCR amplicons 
retrieved from DNA extracted from lab-cultured yogurt containing probiotic 
powder. Isolate sequences = purple circles, clone sequences (yogurt or powder) 
= tan squares. Distance bar represents 0.1 substitutions per base. 
 
 
Figure 2-17. Treatment of gut microbiota intact mice with yogurt has a 
modest effect on parasite burden. Mice were treated 5-6 times/week with 
yogurt for 3 weeks prior to P. yoelii infection and 3 times per week following 
infection. A. Percent parasitemia following P. yoelii infection. B. AUC analysis. 
Data were analyzed by unpaired two-tailed t test. C. Survival of mice following 
infection. Survival curves were analyzed by Log-rank (Mantel-Cox) test. A-C. 





Figure 2-18. Susceptible mice treated with yogurt have decreased 
parasitemia and morbidity. Jax and NCI mice were left untreated (control), 
treated with antibiotics for three-weeks then left untreated for three additional 
weeks (Abx), left untreated for three-weeks followed by treatment with yogurt 5 
times per week for three-weeks (Yogurt), or treated with antibiotics for three-
weeks followed by treatment with yogurt 5 times per week for three-weeks 
(Abx+Yogurt). Mice were then infected with P. yoelii. Yogurt treated mice 
continued to receive yogurt 5 times per week following infection. A. Percent 
parasitemia following P. yoelii infection. B. AUC analysis. Data were analyzed by 
one-way ANOVA and Tukey’s multiple comparison post-test. C. Percent weight 
loss following infection. Data were analyzed by one-way ANOVA. A-C. Data 
(mean±S.E.) are cumulative results (n=3-10 mice/group) from two experiments. * 
p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, n.s. = not significant. 
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Figure 2-19. Resistant Jax mice have an elevated cellular and humoral 
immune response to Plasmodium. Jax and NCI mice were infected with P. 
yoelii. Total number of A. CD4+CD11ahiCD49dhi cells, B. T follicular helper 
cells, and C. germinal center (GC) B cells per spleen on the indicated day. Data 
(mean±S.E.) are cumulative results (n=5-10 mice/data point) from three 
experiments. D. Serum MSP119-specific antibody endpoint titers. Data 
(mean±S.E.) are cumulative results (n=3-7 mice/data point) from two 
experiments. Data were analyzed by unpaired two-tailed t test. * p < 0.05, ** p < 
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Figure 2-20. Gating strategy for T cell and B cell populations in Jax and NCI 
mice infected with P. yoelii. Jax and NCI mice were infected with P. yoelii. 
Representative contour plots and histograms are from day 21-post infection. A. 
Representative contour plots and histograms showing gating strategy of CD45.2+ 
cells. B. Representative contour plots showing gating strategy for T cell subsets: 
CD4+ T cells, P. yoelii-specific CD4+ T cells (CD4+CD49dhiCD11ahi), and T 
follicular helper (Tfh) cells (CD4+ CD44hiCXCR5+PD-1+). C. Total number of 
CD4+ cells per spleen. D. Representative contour plots and histograms showing 
  68
gating strategy of B cell subsets: CD19+ B cells and GC B cells 
(CD19+GL7+CD95+). E. Total number of CD19+ cells per spleen. Data 
(mean±S.E.) are cumulative results (n=5-10 mice/data point) from three 




SEVERITY OF PLASMODIUM INFECTION IN MICE DIFFERNTIALLY 
AFFECTS GUT-LIVER AXIS HOMEOSTASIS 
 
Malaria is a significant global health disease, with 216 million infections 
and 445,000 deaths occurring annually. With no effective vaccine and increasing 
anti-malarial drug resistance, it is imperative to gain a greater appreciation of the 
factors that influence the pathogenesis of this infectious disease. Recent reports 
have demonstrated dual interactions between gut microbiota and malaria. For 
example, in specific Plasmodium-mouse strain combinations, malaria has been 
shown to transiently modulate gut microbiota and cause intestinal shortening, 
indicating a disruption of gut homeostasis. However, these changes have not 
been characterized in the context of mild versus severe malaria. We show that 
severe Plasmodium infection in mice disrupts homeostasis along the gut-liver 
axis in multiple ways compared to mild infection. High parasite burden results in 
a larger influx of immune cells in the lamina propria and mice with high 
parasitemia display specific metabolomic profiles in the ceca and plasma during 
infection compared to mice with mild parasitemia. Liver damage was also more 
pronounced and longer lasting during severe infection, with concomitant changes 
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in bile acids in the gut. Finally, severe Plasmodium infection changes the 
functional capacity of the microbiota, enhancing bacterial motility and amino acid 
metabolism in mice with high parasite burden compared to a mild infection. 
Taken together, Plasmodium infections have diverse effects on host gut 
homeostasis relative to the severity of infection. 
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Introduction 
Malaria infections, caused by Plasmodium, have long been of global 
clinical importance, with 216 million infections and approximately 445,000 deaths 
in 20161. Several factors play a role in disease epidemiology, such as emerging 
resistance to frontline antimalarials124,125 and the lack of an effective vaccine. 
Further complicating efforts to eradicate this parasite is the dual life cycle 
wherein Plasmodium sexually reproduces and develops in its reservoir, the 
Anopheles mosquito, before being transmitted to the human host during a 
mosquito blood meal3,126. Within the human host the parasite undergoes 
development in the liver followed by asexual reproduction in red blood cells3,126. 
The liver stage is clinically silent, while the blood stage is associated with the 
clinical symptoms of malaria, including fever, anemia, and coma3,126. 
 The microbiota, which is the microbial consortia associated with the host, 
has been connected to host homeostasis and development. Bacteria are the 
most common inhabitants, while fungi and archaea make up smaller parts of the 
consortia. Indeed, recent calculations estimate there are approximately 3-4 x 1013 
associated bacteria, corresponding to a bacteria:human cell ratio from around 1.3 
to 2.3 depending on variables such as gender, age, and obesity127. The host 
microbiota has been examined in different sites such as skin128,129 and lung130-132, 
but the gut microbiota has by far been the most studied. Intriguingly, the gut 
microbiota has also been shown to interact with the central nervous system in the 
“gut-brain axis”, and is involved in processes like host development, circadian 
  72
rhythm, and disease states such as major depression81,133. The gut microbiota 
has been shown to play a role in immunity, both locally in the intestine but also 
systemically in modulating host responses to diseases such as influenza and 
Klebsiella pneumonia71,73,134,135. 
 Likewise, it has previously been shown that Plasmodium infection and the 
severity of malaria can be modulated by the composition of gut microbiota. 
Antibody cross-reactivity with the gut commensal E. coli O86:B7 and the 
expressed malaria antigen Galα1-3Galβ1-4GlcNAc-R (alpha-gal) leads to 
inhibition of sporozoite transmission through the skin74. We have previously 
observed that gut microbiota composition in mice can modulate the severity of P. 
yoelii 17XNL (Py) infection, and that susceptibility or resistance can be 
transferred to germ-free mice by transferring cecal contents from either 
susceptible or resistant mice136. Conversely, the Plasmodium infections also 
affect gut microbiota. Following Plasmodium berghei ANKA infection in C57BL/6 
mice, which causes experimental cerebral malaria in C57BL/6 mice, gut 
microbiota became dysbiotic, or disrupted, as the infection progressed38. The 
authors concluded that the change in microbiota composition was due to P. 
berghei ANKA infection and not infection-associated inflammation, as the 
microbiota changes occurred before the intestines underwent inflammation-
mediated changes such as the intestine and villi shortening38. In contrast, there 
were little to no changes in gut bacteria observed in P. berghei ANKA infected 
BALB/c mice38. Finally, C57BL/6 mice infected with Plasmodium yoelii nigeriensis 
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also exhibited changes in gut microbiota composition during peak infection, 
although these changes were transient with the composition returning to baseline 
following resolution of the infection37.  
 While it has been shown that gut microbiota affects and is affected by 
Plasmodium infection, these findings have not been explored in the context of 
mild vs. severe malaria. Using a mouse model of malaria, we show that severe 
malaria differentially disrupts gut homeostasis compared to a mild infection. 
Severe Py infection leads to more proinflammatory cell infiltration in the intestinal 
lamina propria, as well as differential metabolic changes during infection. Severe 
infection also leads to prolonged liver damage; surprisingly, mild Py infection led 
to longer-lasting changes in cecal bile acid abundances. Following infection there 
were shifts in the taxonomy of gut bacteria in both mild and severe Py infections, 
with the composition of the gut bacteria becoming more similar over the course of 
infection. Of note, these changes did not impact the severity of malaria in 
subsequent infections. Finally, severe infection drives a differential functional 
profile in the gut microbiota compared to mild infection. These results show that 
severe Py infection can differentially disrupt gut homeostasis in numerous ways. 
 
Results 
Intestinal Permeability Increases During Py Infection but is not a Function 
of Parasite Burden 
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 During Py infection, mice from Taconic Biosciences (Tac) and Charles 
River Laboratories (CR) show different parasitemia kinetics, leading to 
significantly different overall parasite burdens with CR mice exhibiting higher 
parasitemia than Tac mice (Fig. 3-1A and B). CR mice also display more weight 
loss, indicating greater morbidity during infection (Fig. 3-1C). These 
characteristics allow us to contrast a relatively mild Py infection in Tac mice to a 
severe Py infection in CR mice. We also looked at intestinal permeability during 
infection as one factor in gut homeostasis. While there were increases in 
intestinal permeability within the Tac and CR groups during infection, there were 
no differences between Tac and CR (Fig. 3-1D and E) indicating that increased 
intestinal permeability is not a function of overall parasite burden. 
 
The Lamina Propria Immune System Undergoes Differential Changes 
During Mild and Severe Py Infections 
 The lamina propria (LP) houses a very diverse immune cell population 
responsible for maintaining tolerance to gut microbiota137-139. Additionally, it has 
been shown that a systemic infection like influenza can modulate the LP immune 
system71,73. With this in mind, we followed specific immune cell populations in 
both the small intestine (SI) LP and large intestine (LI) LP during Py infection. In 
general, CR mice had significantly more immune cells in the SI LP during 
infection than Tac mice (Fig. 3-2 and Fig. 3-9), particularly as the infection 
progressed and parasitemia peaked around days 14-21 post-infection (p.i.). More 
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specifically, macrophages (CD45+SiglecF-CD11b+Ly6G-Ly6C-F4/80+) and CD8 T 
cells (CD45+CD8+) peaked at day 14 (Fig. 3-2B, I; Fig. 3-9), while monocytes 
(CD45+SiglecF-CD11b+Ly6G-Ly6C+) and neutrophils (CD45+SiglecF-
CD11b+Ly6G+) peaked at day 21 p.i. in CR mice (Fig. 3-2J, K; Fig. 3-9). The 
influx of monocytes and neutrophils indicates a more inflammatory LP 
environment for CR mice at the peak of Py infection, which could cause changes 
in gut microbiota. Tac mice similarly had an increase in CD8 T cells and 
macrophages at day 14, along with a day 14 increase in neutrophils that 
correlate with peak parasitemia in Tac mice (Fig. 3-2B and I-J). Additionally, 
after Py clearance in the Tac SI: CD8 T cells (Fig. 3-2B), macrophages (Fig. 3-
2I), and monocytes (Fig. 3-2J) all increased at day 60 p.i. In the LI LP (Fig. 3-
10), there were fewer changes than in the SI LP: macrophages increased in Tac 
and CR LI at day 14 and day 60 p.i. (Fig. 3-10I) and IL17+ Th17 T cells (Fig. 3-
10H) increased in both Tac and CR mice after Py clearance. While both Tac and 
CR had a significant increase in IL17+ gamma delta T cells (TCR𝛾𝛿; 
CD45+TCR𝛾𝛿+IL17+) at days 7 and 14 p.i., Tac mice had more than CR at day 14 
(Fig. 3-10F). Overall, distinct immune populations change during mild and severe 
malaria, with a potentially more inflammatory environment during severe malaria 
in CR mice.  
 
Gut Microbiota Undergoes Significant Post-Infection Changes but does not 
Affect Susceptibility to Future Infections 
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It has been shown previously that baseline gut microbiota composition in 
resistant and susceptible mice is sufficient to modulate the severity of 
infection136, but it has also been shown that the gut microbiota can experience 
Plasmodium-induced inflammation-related changes37,38. To initially determine 
how severity of infection impacts changes to bacterial community compositions 
over the course of infection, mice from Tac and CR were infected with Py and 
cecal contents were extracted for 16S rRNA (V6-V8) sequencing. While this was 
not a truly longitudinal analysis, it showed changes in both Tac and CR mice 
after infection, primarily after clearance of Py (Fig. 3-11). To confirm these 
results in a longitudinal analysis and increase the taxonomic assignment depth, 
Tac and CR mice were infected with Py and fecal pellets were collected at days 
0, 7, 14, 21, 28, 42, and 56 p.i. for analysis of gut bacteria (Fig. 3-3A). Extracted 
DNA from fecal pellets was subjected to bacterial community analysis using 16S 
rRNA gene sequencing based on a new technology that simultaneously utilizes 
all 9 hypervariable regions (manuscript describing this method is under peer 
review).  
During Py infection, there are changes in the relative species abundance 
in both Tac and CR mice (Fig. 3-3B). For example, the Tac microbiota becomes 
more diverse as soon as 7 days p.i., with a significant increase in species 
diversity (alpha diversity) measured by observed OTUs (Fig. 3-3C). This 
increase is based on the appearance of different bacterial species such as 
Stomatobaculum longum that are not present at day 0 p.i. (Fig. 3-3B,C). 
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Compared to the Tac microbiota, the CR microbiota is significantly more diverse 
before and during infection (Fig. 3-3C); however, the species diversity of the CR 
microbiota does not change from baseline (Fig. 3-3C). The beta diversity, or 
dissimilarity, of bacterial communities in both the Tac and CR mice increases 
significantly during infection compared to their respective baselines, with an 
earlier increase in Tac mice at day 7 (Fig. 3-3D). The increase in beta diversity 
illustrates the taxonomic changes that occur due to Py infection. Of note, Bray-
Curtis dissimilarity values range from 0 (identical similarity) to 1.0 (complete 
dissimilarity). Thus, while the increases in beta diversity are significant, they are 
relatively modest in both Tac (mean; day 0 = 0.19 to day 56 = 0.40) and CR mice 
(mean; day 0 = 0.12 to day 56 = 0.23) with both Tac and CR communities, 
respectively, remaining relatively similar amongst themselves. These data 
demonstrate that Py infection alone, in contrast to the severity of infection, 
influences the observed changes in gut bacterial communities. Interestingly, the 
dissimilarity between the Tac and CR microbiota compositions decreases during 
infection (Fig. 3-3E), demonstrating a moderate convergence in the different 
microbiota compositions. Since different gut microbiota profiles have been shown 
to modulate susceptibility to Py infection136, these changes were investigated to 
determine how they impact susceptibility to future Py infections.  
 Mice infected with Py develop sterilizing immunity to Py after one infection, 
precluding the ability to directly reinfect these mice. Therefore, cecal contents 
were taken from Py-infected Tac and CR mice on days 56, 57, 60, and 61 p.i. 
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and gavaged into germ-free (GF) mice (Fig. 3-3A). The recipient mice, along with 
non-gavaged control Tac and CR mice, were infected with Py seven days after 
the last cecal-content transplant and parasitemia was tracked. 
 To confirm the GF mice had been colonized properly, fecal samples from 
recipient mice were collected on the day of Py infection (Fig. 3-3A) for bacterial 
community analysis. The species diversity of both the GF+PyTac and GF+PyCR 
samples was similar to the input diversity, which means the GF mice were 
successfully colonized and their gut bacteria populations mirror the donor mice 
that had previously been infected with Py (Fig. 3-3F). More specifically, the Tac 
control samples had significantly lower species diversity than the input contents 
(Fig. 3-3F), confirming the observed changes during Py infection (Fig. 3-3C). 
Similarly, the Tac input and GF+PyTac samples are significantly dissimilar to the 
Tac controls but not each other (Fig. 3-3G). In the CR samples, the CR input 
samples had a slightly higher species diversity than the CR control (Fig. 3-3F), 
but this did not result in a bacteria community that was overall dissimilar (Fig. 3-
3G). Following infection, the GF+PyTac and GF+PyCR contents phenocopied 
parasitemia in the respective Tac and CR control mice with regards to the 
infection kinetics (Fig. 3-3H) and overall parasite burden (Fig. 3-3I). These data 
suggest that Py-induced changes in gut bacterial communities do not change 
resistance or susceptibility to future Py infections. 
 
Cecal and Plasma Metabolite Profiles Vary Between Tac and CR Mice 
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One mechanism by which gut microbiota can influence host homeostasis 
is through the production of metabolites. Different metabolites can have various 
effects on the host: nucleotides in the gut can reduce inflammation, while 
tryptophan metabolites can activate the aryl hydrocarbon receptor (AhR) and 
lead to an anti-inflammatory and xenobiotic clearance response140-142. To this 
end, SI and cecal contents as well as plasma were extracted from mice at days 
0, 7, 14, 21, 28, and 60 p.i. and characterized by mass spectrometry.  
 In the SI, no distinct clustering between Tac and CR samples is observed, 
with the exception of two noted outliers, one Tac sample at day 7 p.i. and one CR 
sample at day 0 p.i. (Fig. 3-4A-B). In contrast, the cecal PCA plot shows distinct 
differences between Tac mice and CR mice (Fig. 3-4C). In the CR mice, a similar 
metabolite profile is seen at days 0, 7, and 14 p.i.; however, at day 21 p.i., which 
correlates to the peak of severe infection, the metabolites in the cecum become 
much more abundant (Fig. 3-4D). This enrichment decreases by day 28 p.i. to 
below-baseline levels for metabolites in the bottom-half of the heatmap and 
remain low even one month after clearance of the infection. In contrast to CR 
mice, cecal metabolites remain largely stable in Tac mice over the course of 
infection, with only a few metabolites decreasing at days 28 and 60 p.i. (Fig. 3-
4D). Tac and CR plasma metabolite profiles follow similar kinetics during 
infection. The most pronounced changes during infection are the similar shifts in 
metabolites at the peak of infection: day 14 p.i. in Tac mice and days 14 and 21 
p.i. in CR mice (Fig. 3-4E). The clustering of these samples explains a robust 
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70% of the variation. The metabolite profiles seen in naïve mice become 
inverted, with abundant metabolites at day 0 p.i. becoming depleted, while less 
abundant metabolites becoming enriched at the peaks of infection in Tac and CR 
mice (Fig. 3-4F). In addition, after Py clearance, the metabolite profiles in both 
Tac and CR mice largely return back to pre-infection levels by day 60 p.i. (Fig. 3-
4F). 
Overall, Tac and CR mice have different metabolite profiles before and 
during infection, and the changes in cecal metabolite concentrations during 
infection correlates with the severity of infection. Meanwhile, the plasma 
metabolite dynamics appear to depend on the kinetics of infection more so than 
the severity of infection.  
 
Py Infection Causes Differential Liver Damage in Mice During Py Infection 
Differential cecal metabolites, noted gross anatomical changes in the liver 
of Py infected mice (data not shown), and the observation that Plasmodium 
infections cause fibrotic lesions in the liver143 led us to investigate a potential role 
of the liver in Py-induced changes in gut homeostasis. The gut-liver axis has 
been well-established144-147, and can influence metabolite profiles and microbial 
community structures through different mechanisms. Livers were extracted from 
mice at days 0, 7, 14, 21, and 28 days post-Py infection and stained with 
hematoxylin and eosin (H&E). Before infection, normal liver structure is observed 
in Tac and CR mice (Fig. 3-5). After Py infection, immune cells begin to infiltrate 
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the liver and disruption of the liver architecture can be seen. In CR mice, the 
infiltrating cells remain in close proximity to the vasculature, while in Tac livers 
the infiltrating cells appear to invade further into the liver tissue (Fig. 3-5). At day 
14, which is around peak parasitemia for Tac mice, immune cell infiltration 
increases and modest hemozoin deposition is seen (Fig. 3-5). In CR mice at day 
14 p.i., the immune cell infiltration has progressed deeper into the tissue, and 
more extensive hemozoin deposition is seen compared to the Tac livers; the liver 
architecture also becomes further disrupted (Fig. 3-5). By day 21 p.i., Tac mice 
have cleared the infection; however, low levels of hemozoin and infiltrating 
immune cells are still present (Fig. 3-5). At day 28, the Tac liver architecture has 
returned to its pre-infection state and the infiltrating immune cells have left, but 
small amounts of hemozoin can still be seen within the tissue (Fig. 3-5). In 
comparison, day 21 p.i. is peak parasitemia for the CR mice, which display a 
more severe infection. Consistently, the liver architecture is highly disrupted, with 
infiltrating immune cells and hemozoin scattered throughout the tissue (Fig. 3-5). 
Liver architecture is partially restored by day 28 with only few infiltrating immune 
cells around the vasculature (Fig. 3-5). Compared to Tac livers at day 21 and 
day 28 p.i., there is notably more hemozoin in CR livers. Collectively, the severity 
of blood stage infection leads to much more pronounced and prolonged damage 
to the liver. 
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Tac and CR Mice Have Different Bile Acid Profiles Before and During Py 
Infection 
One mechanism by which the liver can influence gut microbial 
communities is through bile acid production. Bile acids are detergent-like 
molecules that can be metabolized by gut bacteria, disrupt bacterial cell 
membranes, and act as signaling molecules to the intestinal epithelial cells148-151. 
We hypothesized that bile acid production would be altered as a function of the 
severity of infection. To test this hypothesis, bile acids were analyzed at days 0, 
7, 14, 21, 28, and 60 p.i. in the SI, cecum, and plasma of Tac and CR mice. In 
the SI, the most notable pattern in bile acid expression is that the Tac mice have 
a significant decrease in almost half of the detected bile acids at day 14 
compared to pre-infection bile acid levels (Fig. 3-6A, Fig. 3-12). In terms of 
individual bile acids, conjugated bile acids glycochenodeoxycholic acid 
(GCDCA), taurochenodeoxycholic acid (TCDCA), and taurodeoxycholic acid 
(TDCA) in Tac and CR show significant changes at several time points (Fig. 3-
12). 
 In the cecum, CR mice tend to have higher relative bile acid concentration 
before and during infection compared to Tac mice (Fig. 3-6B, Fig. 3-13). 
However, both Tac and CR mice exhibit a significant decrease in specific bile 
acids during infection, with the largest changes occurring in the taurine-
conjugated bile acids. In particular, taurine-conjugated bile acids become 
depleted at day 14 in Tac mice with a mild recovery before a long-term depletion 
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up to day 60 p.i. (Fig. 3-6B, Fig. 3-13). CR mice have a similar depletion at day 
14 that extends to day 21 p.i., consistent with the more severe infection in CR 
mice, but these bile acid levels return to baseline levels by clearance of the 
parasite at day 28 p.i. (Fig. 3-6B, Fig. 3-13). Additionally, several bile acids are 
significantly higher in CR mice over the course of the infection compared to Tac, 
such as glycocholate (GCA) and omega-muricholate (oMCA) (Fig. 3-6B, Fig. 3-
13). 
 Plasma bile acids were low in abundance and were largely unchanged 
over the course of infection. The two noted exceptions were in Tac mice: glycine-
conjugated bile acids GCDCA and glycodeoxycholate (GDCA) decrease at days 
7 and 14 p.i. and day 7 p.i., respectively (Fig. 3-6C, Fig. 3-14); alpha-muricholate 
(aMCA) significantly decreases at days 7 and 14 p.i. while beta-muricholate 
(bMCA) is significantly more abundant at those same time points (Fig. 3-14). 
 Like the metabolomics data (Fig. 3-4), the cecal bile acid profiles in Tac 
and CR are different at baseline and change differentially due to mild or severe 
infection. In this case, however, the milder Py infection induces long-lasting 
depletion of bile acids. 
 
Predicted Functional Changes in the Microbiota Align with Combined 
Datasets 
We have observed many changes within the host and the microbiota 
during infection. To investigate how the observed taxonomic and metabolite 
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profiles interact, PICRUSt was utilized to predict the functional capacity152 of 
cecal bacteria in Tac and CR mice based on the sequencing data in Figure 3-11. 
Once in PICRUSt, KEGG ortholog (KO; a characterized gene or protein within a 
network) abundances were assigned to each sample; KOs were then categorized 
according to the KO reference hierarchy and analyzed153-155. When naïve Tac 
and CR mouse KO abundances are compared, the proportional abundances of 
each category are similar, but in spite of the lower species diversity (Fig. 3-11B) 
the naïve Tac microbiota have approximately 40% more KOs than the CR 
microbiota (Fig. 3-7A,B). “Metabolism” was the largest category, containing 
almost 47% of total KOs during infection. Tac microbiota possess significantly 
more KOs than CR mice at days 0 and 7 p.i., while from day 14 p.i. onward the 
Tac and CR microbiota possess similar KO abundances (Fig. 3-7C). The 
observed change in the functional capacity in the CR microbiota by day 14 p.i. 
precedes the large taxonomic changes and metabolomics changes observed at 
day 60 p.i. and day 21 p.i., respectively. Each level 1 KEGG category follows this 
same pattern except for one, “Cellular Processes”; Tac and CR microbiota are 
significantly different at day 7 p.i., but not at day 0, indicating that Py infection 
differentially affects the Tac and CR microbiota during early infection (Fig. 3-7D). 
Similarly, the CR microbiota undergoes significant functional changes in Cellular 
Processes at day 21 p.i. compared to the day 0 p.i. CR microbiota (Fig. 3-7D). 
The only level 2 subcategory under Cellular Processes that also changes 
significantly from day 0 to day 21 p.i. is “Cell Motility”, which includes flagellar 
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assembly and bacterial chemotaxis (Fig. 3-7E). Finally, the Cellular Processes 
KOs at day 28 and day 60 p.i. correlate with the taxonomic changes: the Tac 
microbiota changes significantly at day 28 p.i., while the CR microbiota shows a 
delayed change at day 60 p.i., effectively “catching up” to the Tac microbial 
community structure. When comparing the PICRUSt data to the taxonomic data 
in Fig. S3, the bloom in the S24-7 bacterial family (Fig. 3-11A) correlates to a 
loss in the Cellular Processes functional capacity, and more specifically a loss in 
the microbiota’s capacity for cell motility (Fig. 3-7D,E). Taken together, naïve Tac 
and CR microbiota each have distinctly different functional profiles; after Py 
infection, the functional capacity of these two bacterial communities become 
indistinguishable, even after the parasite is cleared. In the case of some KO 
categories like Cellular Processes and Cell Motility, the KO abundances correlate 
closely with the taxonomic changes seen in Tac and CR microbiota during 
convalescence.  
 The metabolomics data can be used to validate the predicted functionality 
of the cecal microbiotas. Tac mice are predicted to have a significantly higher 
functional capacity for “Amino Acid metabolism” (Fig. 3-7F) compared to CR 
mice. When compared to the observed metabolite abundances, the top enriched 
pathways at day 0 p.i. are related to metabolism of various amino acids, and this 
enrichment is associated with the Tac phenotype (Fig. 3-7G). In contrast, at day 
21 p.i., the enriched pathways have changed and the majority are now 
associated with the CR phenotype (Fig. 3-7H); this shift correlates to the large 
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increase in metabolite abundances in the CR cecum at day 21 p.i. (Fig. 3-4D). 
Overall, the functional predictions in the ceca of Tac and CR mice fit well with the 
taxonomic and metabolomic data presented. 
 
Discussion  
In this study, we have shown that gut homeostasis is differentially 
disrupted by severe malaria compared to mild malaria. We examined several 
factors of gut homeostasis, including intestinal permeability, the intestinal 
immune system, gut microbiota and metabolites, and the gut-liver axis. 
Altogether, severe malaria differentially influences gut homeostasis with distinct 
actions (Fig. 3-8). During infection, the LP in CR mice with severe malaria has a 
larger influx of CD8 T cells, monocytes, neutrophils, and TCR𝛾𝛿 cells, all of which 
can produce proinflammatory cytokines. The microbiota of both Tac and CR mice 
differentially change during infection, with larger changes occurring earlier in Tac 
mice. The taxonomic changes in Tac and CR mice lead to enrichment of different 
bacterial species, highlighting the differential modulation of microbiota by Py 
infection. Initially, CR microbiota have a sparse predicted functional profile 
compared to Tac microbiota; during infection, the CR and Tac predicted 
functional capacity becomes more similar, reflecting the taxonomic similarity at 
the family level post-Py clearance. The cecal metabolite profiles in CR mice 
reflect the parasite burden, with the peak of infection mirroring a large increase in 
metabolite abundances, while Tac mice do not show a similar increase. CR mice 
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also show major liver damage during infection with more extensive damage and 
hemozoin deposition compared to asymptomatic Tac mice. Finally, cecal bile 
acid profiles in Tac mice show a prolonged depletion during infection compared 
to CR mice, with CR bile acid abundances generally returning to baseline levels 
by days 28 and 60 p.i. Taken together, these data show patterns of gut 
homeostasis disruption during severe malaria.  
 While previous studies have shown changes to gut microbiota during 
Plasmodium infection as well, our data is unique in that it shows that there are 
long-term changes that occur during infection that persist after the infection is 
cleared. Mooney et al. showed that during Plasmodium yoelii nigeriensis 
infection, there were shifts in murine gut microbiota, but these returned to 
baseline within 30 days p.i. and were taxonomically restricted primarily to the 
phylum level with only a few noted changes at the genus level37. Taniguchi et al. 
also showed shifts in the gut microbiota of C57BL/6 mice infected with P. berghei 
ANKA, which models cerebral malaria, but not BALB/c mice, which do not model 
cerebral malaria38. Of note, all the P. berghei ANKA infected C57BL/6 mice 
succumbed to cerebral malaria, so it is unknown if these changes affect parasite 
burden, immunity to malaria, or would remain after clearance of infection. We 
have extended these analyses to show that the gut microbiota undergoes long-
term, persistent changes down to the species level due to Py infection and that 
these changes do not affect susceptibility to future Py infections. 
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 We have also looked more closely at the LP immune response during Py 
infection. Previously, it had been observed that during P. yoelii nigeriensis 
infection, mononuclear cells infiltrate the LP up to 10 days p.i., with a large 
portion of these identified as inflammatory monocytes (Ly6C+ Ly6G-)38. Using Py 
17XNL instead of P. yoelii nigeriensis, we have also found that large numbers of 
monocytes infiltrate into the LP of mice with high parasitemia 21 days p.i. before 
returning to baseline, while mice with low parasitemia show a significant increase 
60 days p.i. In addition, we have observed a significant increase in macrophage 
infiltration at 7 days p.i. and 60 days p.i. We have corroborated the previously 
observed early mononuclear cell infiltration and extended the analysis further p.i. 
and to more cell types. 
 A potential mechanism for how severe malaria differentially impacts gut 
homeostasis may be due to parasite sequestration in the gut vasculature. In 
severe malarial anemia in humans, for instance, the bulk of parasite 
sequestration occurs in the vasculature of the small and large intestines; patients 
with cerebral malaria also show a large amount of parasite sequestration in the 
gut along with the brain156. Sequestration in the vasculature could lead to 
inflammation which in turn would damage the gut tissue, disrupting tissue 
homeostasis.  
 One promising avenue for further investigation within the malaria-gut 
microbiota axis involves bile acid metabolism in the gut. In the intestine, bile 
acids aid in digestion but can also behave as signaling molecules or 
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bacteriostatic agents. As detergent-like molecules, bile acids can weaken or 
destroy bacterial cell membranes, keeping bacterial growth in check151,157. In 
both Tac and CR mice, the initial liver damage and depletion of bile acids 
correlates with the increase in gut bacterial diversity during and after infection, 
pointing to the potential role of bile acids in shaping the gut microbiota before and 
during Py infection.  
Signaling by bile acids in the intestine can occur through the G protein-
coupled receptor TGR5. CDCA and lithocholic acid (LCA)/DCA are the strongest 
ligands, with other bile acids binding with lesser affinity; conjugation with taurine 
or glycine makes binding and activation more effective148-150. TGR5 is found in 
the intestine as well as in extra-intestinal tissues such as lung, spleen, and bone 
marrow158. Since plasma levels of bile acids did not vary between Tac and CR 
mice during infection, it is unlikely that activation of TGR5 in extra-intestinal 
tissue is involved. However, TGR5 activation on intraepithelial lymphocytes leads 
to the expression of GLP-1 (glucagon-like peptide 1) which in turn inhibits 
proinflammatory cytokine production159. As Tac mice have a greater abundance 
of taurine-conjugated bile acids than CR mice initially, TGR5 signaling may be 
play a protective anti-inflammatory role early in Py infection.  
 While there is still much work to be done, these results identify the 
complex network of interactions that influence gut homeostasis during Py 
infection in mice and provide an extensive characterization of how different 
factors in gut homeostasis respond during mild versus severe Py infection. Many 
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of the perturbations in gut homeostasis were associated with a more severe 
infection. Given that many parasitized red blood cells sequester in intestinal villi 
in humans, it is paramount that future work begin assessing the effect of 
Plasmodium infections on human gut homeostasis. 
  
Materials and Methods: 
Animals and Housing: 
 Female C57BL/6 mice 6-8 weeks old were purchased from Taconic 
Biosciences (Hudson, NY) and Charles River Laboratories (Wilmington, MD). 
Germ-free (GF) mice were purchased from Taconic Biosciences. All mice were 
housed in a specific pathogen-free facility and acclimatized for a minimum of 7 
days before starting experiments. Animals were fed the NIH-31 diet (Modified 
Open Formula Mouse/Rat Irradiated Diet; Harlan 7913; Envigo, Indianapolis, IN) 
and provided autoclaved, non-acidified municipal water ad libitum. The mice 
were kept on a 12-hour light/dark cycle from 6 AM to 6PM and 6PM to 6AM, 
respectively. All animal experiments were carried out at the University of 
Louisville in compliance with local and national regulations of laboratory animal 
welfare. Additionally, all animal care and use procedures were approved by the 
University of Louisville Institutional Animal Care and Use Committee. 
 
Plasmodium Infection and Evaluation of Parasitemia: 
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 Mice were infected with Plasmodium yoelii 17XNL by intravenous injection 
of 1x105 infected red blood cells (RBCs) in 200 uL of saline prepared from frozen 
stock. Parasitemia (i.e. percentage of total infected RBCs) was evaluated by flow 
cytometry between days 5-30 post-infection (p.i.) via blood taken from the tails of 
infected mice. Approximately 5 µL of whole blood was diluted in 100 µL of PBS 
followed by fixation in 0.00625% glutaraldehyde. The samples were then stained: 
CD45.2-APC (clone 104; Biolegend, San Diego, CA), Ter119-APC/Cy7 (clone 
TER-119; Biolegend, San Diego, CA), dihydroethidium (MilliporeSigma, St. 
Louis, MO), and Hoechst 33342 (MilliporeSigma, St. Louis, MO). After staining, 
samples were resuspended in flow cytometry buffer and analyzed; RBCs were 
gated by Ter119+CD45.2- followed by gating the infected subpopulation on 
dihydroethidium+Hoechst 33342+ to find the percentage of infected RBCs. 
 
GF Cecal Content Transplant: 
Tac and CR cecal donor mice were infected with Py; at day 56 p.i., GF 
mice were received. GF mice were colonized immediately upon arrival with cecal 
contents from either the infected Tac or CR donor mice. GF mice were gavaged 
daily with cecal contents for a total of 4 treatments and then rested for 1 week 
before Py infection. Fecal pellets were collected after gavage to ensure 
colonization recapitulation of donor microbiota. 
 
Liver Histology: 
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 Liver samples were collected from mice at days 0, 7, 14, 21, and 28 p.i. 
Livers were extracted from mice, trimmed of connective tissue, and placed into 
Tissue-Tek Uni-Cassettes (Sakura Finetek, Torrance, CA) in 10% neutral 
buffered formalin (MilliporeSigma, St. Louis, MO) for fixation. Livers were then 
processed using a graded ethanol series and embedded in paraffin. The paraffin 
sections were cut into 5 μM-thick slices using a microtome and stained with 
hematoxylin and eosin (H&E). All stained sections were examined by light 
microscopy using an Olympus BX41 microscope. Representative images are 
shown (magnification - 20X). 
 
Intestinal Permeability Assay: 
 Intestinal permeability was measured using 4kD FITC-dextran 
(MilliporeSigma, St. Louis, MO). Mice were fasted for 4 hours followed by oral 
gavage of ~42mg FITC-dextran/100mg of body weight in 200 µL of PBS, or 
8.4mg/200µL/mouse. Three hours post-gavage, serum was collected, diluted 1:1 
in PBS to reach 100 µL final volume, and read on a spectrophotometric plate 
reader for fluorescence intensity (Excitation at 485 nm and emission at 528 nm).  
 
Lamina Propria Immune Cell Analysis: 
 Lamina propria (LP) immune cells were isolated at days 0, 7, 14, 21, 28, 
and 60 p.i. using the mouse Lamina Propria Dissociation Kit (Miltenyi Biotec, 
Auburn, CA) according to the manufacturer’s instructions. Briefly, small and large 
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intestines were extracted from mice and cut open longitudinally and laterally into 
approximately 0.5 cm long pieces. The samples were then incubated and 
washed to dissociate the epithelial layer. The resulting samples were then run on 
a gentleMACS dissociator (Miltenyi Biotec, Auburn, CA) and filtered to obtain a 
single-cell suspension. Samples were split and either only surface stained or 
surface stained and intracellularly stained with fluorescence-conjugated 
antibodies. Antibodies were resuspended in FACS buffer (1x PBS, 0.02% sodium 
azide, and 1% FCS) for surface staining for 15 minutes at 4°C followed by 
fixation with Fixation Buffer (Biolegend, San Diego, CA), while intracellular 
staining was carried out with the eBioscience Foxp3/Transcription Factor 
Staining Buffer Set (ThermoFisher, Waltham, MA) according to the 
manufacturer’s instructions. Samples were collected on a BD LSRFortessa (BD 
Biosciences, San Jose, CA) and analyzed using FlowJo software for Mac, 
version 10.4.2 (FlowJo, Ashland, OR).  
 
Marker-Fluorescence Clone Vendor 
CD4-APC-Cy7 RM4-5 Biolegend 
CD8-FITC 53-6.7 Biolegend 
CD45-AF700 104 Biolegend 
TCRgd-BV421 GL3 Biolegend 
CD19-PerCP-Cy5.5 6D5 Biolegend 
Foxp3-PE 150D/E4 Invitrogen 
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CD49b-APC DX5 Biolegend 
RORgt-BV650 Q31-378 BD Biosciences 
IL17A-PE-Cy7 TC11-18H10.1 Biolegend 
CD3-FITC 145-2C11 Biolegend 
CD11c-BV650 N418 Biolegend 
CD11b -PE-Cy7 M1/70 Biolegend 
Siglec F-PE E50-2440 BD Biosciences 
Ly6C-PerCP-Cy5.5 AL-21 BD Biosciences 
Ly6G-APC 1A8 Biolegend 
F4/80-BV421 BM8 Biolegend 
CD16/32 (Fc Block) 2.4G2  
 
Metabolite Screening and Bile Acid Analysis: 
 Ceca, small intestine, and plasma samples were collected from Tac and 
CR mice at days 0, 7, 14, 21, 28, and 60 p.i. The ceca and small intestines were 
flushed with extraction buffer (a mix of 40:40:20 HPLC grade methanol, 
acetonitrile, and water with 0.1% formic acid overall), flash frozen in liquid 
nitrogen, and stored at -80°C. Samples were shipped overnight on dry ice to our 
collaborators for an untargeted metabolomics screen and targeted bile acid 
analysis. Sample preparation was the same for both mass spectrometric 
analyses. Shipped samples were extracted, dried, resuspended and immediately 
placed in a 4º C mass spectrometer autosampler according to a method 
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previously described [19]. 10 μL of sample was injected into the Ultra 
Performance Liquid Chromatography-High Resolution Mass Spectrometer 
(UPLC-HRMS), a Dionex Ultimate 3000 coupled to an Exactive Plus orbitrap 
mass spectrometer (Thermo Scientific, Walham, MA, USA).  
The untargeted metabolomic screen achieved separations using a Synergy 
Hydro-RP column (100 mm x 2 mm, 2.5 μm particle size, Phenomenex, 
Torrance, CA) at a flow rate of 200 μL/min. The mobile phase consisted of 97:3 
HPLC grade water:methanol, 11 mM tributylamine, and 15 mM acetic acid 
labeled as solvent A, as well as HPLC grade methanol, labeled as solvent B. The 
mobile phase gradient was programmed accordingly: From 0 to 5 min, 0% B; 
from 5 to 13 min, 20% B; from 13 to 15.5 min, 55% B, from 15.5 to 19 min, 95% 
B; and from 19 to 25 min, 0% B, Eluent from the column was introduced into the 
mass spectrometer, an Exactive Plus orbitrap (Thermo Scientific, Waltham, MA, 
USA) via an electrospray ionization (ESI) source set to negative mode. 
Instrument settings include: spray voltage of 3 kV, nitrogen sheath gas flow rate 
of 10 units, capillary temperature set at 320º C, and an AGC target set to 3e6. 
Samples were analyzed at a resolution of 140,000 in full scan mode. The scan 
window included 85 to 800 m/z units from 0 to 9 min and 110 to 1000 m/z units 
from 9 to 25 min. Bile acids were analyzed by the same UPLC-HRMS instrument 
and column that was used as in the metabolomics analysis. The column 
compartment was kept at 40º C and the flow rate was kept at 300 μL/min. Mobile 
phase composition was 0.1% formic acid in water labeled as solvent A and 0.1% 
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formic acid in acetonitrile. The mobile phase gradient consisted of: 0% to 100% B 
from 0 to 13 min, 100% B from 13 to 14 min, 100% to 0% B from 14 to 14.5 min, 
0% B from 14.5 min to 20.5 min. Eluent from this method was introduced into the 
mass spectrometer via a heated electrospray ionization (HESI) source also set to 
negative mode. Instrument settings include: spray voltage of 4.2 kV, nitrogen 
sheath gas flow of 25 units, capillary temperature set at 300º C, and a AGC set to 
3e6. Samples were analyzed at a resolution of 140,000 in full scan mode. The 
scan window was from 150-1000 m/z units.  
 The collected data for each tissue was normalized by tissue weight (small 
intestine and ceca) or volume (plasma) followed by median normalization. Tissue 
data was then formatted for and analyzed with MetaboAnalyst v4.0 
(http://www.metaboanalyst.ca/MetaboAnalyst/faces/home.xhtml), an online tool 
for metabolomic analysis160-163. Using the Statistical Analysis tool, PCA plots and 
heatmaps were generated for the untargeted metabolomics screen; for the 
heatmaps, time point groups were collapsed using group averages, and Ward’s 
method was used for the clustering algorithm along with a Euclidean distance 
measure; relative abundance data was autoscaled to account for metabolites 
with very low or very high abundances. For bile acid heatmaps, neither the 
samples or features were clustered. The Enrichment Analysis tool was used to 
identify enriched pathways between Tac and CR mouse cecal samples at day 0 
p.i. The library for analysis was the Pathway-associated Metabolite Sets and only 
metabolite sets containing at least 2 compounds were used. 
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Gut Microbiota Analysis: 
Mouse ceca and fecal pellets were extracted and flash frozen in liquid 
nitrogen followed by storage at -80°C. DNA was extracted using the QIAamp 
PowerFecal DNA kit (QIAGEN, Germantown, MD) according to the 
manufacturer’s instructions. DNA samples were then shipped overnight on ice 
packs to either the Integrated Microbiome Resource within the Centre for 
Comparative Genomics and Evolutionary Bioinformatics at Dalhousie University 
(IMR-CGEB, Halifax, NS, Canada) or the Genome Technology Access Center at 
Washington University (GTAC, St. Louis, MO) for sequencing. Samples 
submitted to the IMR-CGEB were amplified using primers targeting the V6-V8 
hypervariable regions. Sequencing was done on an Illumina MiSeq with 300bp 
paired-end reads. Sequence analysis was done using the Microbiome Helper 
pipeline, which provides wrapper scripts for common bioinformatics tools164. 
Briefly, sequences were inspected with FastQC v0.11.5; the paired-end reads 
were stitched together with PEAR v0.9.6 and filtered with BBMap v37.24 with a 
quality score cutoff of 30165-167. The filtered FASTQ files were converted to 
FASTA using the FASTX toolkit v0.0.13.2 and chimeras were removed with 
VSEARCH v1.11.1168,169. QIIME v1.9.1 was then run for open reference OTU 
picking using SortMeRNA v2.0 and SUMACLUST v1.0.20 for reference picking 
and de novo OTU picking; alignment was done using PyNAST v1.2.2 and 
Greengenes 13_8170-174. The resulting OTU table was cumulative sum scaled 
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(CSS). Analyses were done within QIIME to produce taxa plots as well as 
calculate alpha diversity and Bray-Curtis beta diversity. 
 Samples submitted to the GTAC were amplified using a novel approach 
that consists of 12 primer pairs that span portions of all 9 of the 16S rRNA 
hypervariable regions175. Upon receiving the OTU table from GTAC, it was CSS 
normalized and analyzed within QIIME to produce taxa plots and calculate alpha 
diversity and Bray-Curtis beta diversity. Both the map file and OTU table used for 
analyses are included as supplementary data as Additional Files 8 and 9, 
respectively. 
 PICRUSt was used to predict the functional capacity of the samples sent 
to the IMR-CGEB152. The OTU table was filtered to remove de novo OTUs to 
produce a compatible OTU table. After filtering, the OTU table was uploaded to 
the Langille Galaxy server (http://galaxy.morganlangille.com/) running PICRUSt 
v1.1.1 for normalization and analysis. All analyses used KEGG Orthologs for 
functional predictions. 
 The joint analysis of the PICRUSt data and metabolite data utilized 
MetaboAnalyst’s Network Explorer tool. The KOs and metabolites were added as 
lists without fold changes for the day 0 time points in Tac and CR mice. The 
mode of analysis used the KEGG Global Metabolic Network and the table 
containing the significantly enriched pathways was downloaded. 
 
Statistical Analysis: 
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Statistical analyses were performed using GraphPad Prism 7 software 
(GraphPad Software, La Jolla, CA, USA); the alpha value for each analysis was 
set at 0.05. Specific analyses are described in figure legends. For area under the 
curve (AUC) parasite burden analyses, the trapezoidal rule was used:  
AUC(t1-t-last) = Σ (pi + pi+1)*(ti+1-ti)/2 
where “p” is percent parasitemia at the designated time point “t”123.  
  100 
Figures and Figure Legends 
 
Figure 3-1. Susceptibility to Plasmodium infection varies between vendors. 
C57BL/6N mice from Taconic (Tac) and Charles River (CR) were infected with P. 
yoelii (Py). A. Percent parasitemia (percentage of red blood cells (RBCs) infected 
with Py) over the course of infection. Individual time points between Tac and CR 
were analyzed by unpaired two-tailed t-test. B. Area under the curve (AUC) 
analysis of percent parasitemia. Data were analyzed by unpaired two-tailed t-
test. C. Percentage of weight lost post-infection (p.i.). Individual time points were 
analyzed by unpaired two-tailed t-test. D. FITC-dextran concentrations in serum 
over the course of infection. E. Data from panel D normalized to the Day 0 time 
point to show fold changes. All data were analyzed by unpaired two-tailed t-test. 
A-C. Data (mean±SE) are cumulative results (n=3-5 mice/group) of two 
experiments. D-E. Data (mean±SE) are cumulative results of 3 experiments 
  101 




Figure 3-2. Small intestine lamina propria immune system changes during 
Py infection. Total cell numbers of A. CD45+ cells, B. CD8+ T cells, C. CD4+ T 
cells, D. Tregs, E. Gamma delta T cells (TCR𝛾𝛿), F. IL17+ TCR𝛾𝛿 G. Th17 cells, 
H. IL17+ Th17 cells, I. Macrophages, J. Monocytes, and K. Neutrophils. Each 
time point was compared by one-way ANOVA with Tukey’s post-hoc multiple 
comparison test. Data (mean±SE) are cumulative results of 2 experiments (3 
mice/group/experiment). 1 symbol, p < 0.05; 2 symbols, p < 0.01; 3 symbols, p < 
0.001; 4 symbols, p < 0.0001. * = Tac and CR SI comparisons; a = Tac SI 
comparisons to Day 0; b = CR SI comparisons to Day 0. 
  102 
 
 
Figure 3-3. Gut bacterial community changes occurring post-Py infection 
do not change susceptibility to future Py infections. A. Experimental design 
of time course and cecal transplants along with fecal pellet collection times. B. 
Relative taxonomic abundance of bacterial species during Py infection. C. Alpha 
diversity (sample richness) between Tac and CR mice during infection using 
observed OTUs. Data were analyzed with a repeated measures two-way ANOVA 
with Dunnett’s post-hoc multiple comparison test for comparisons to Day 0 p.i. 
and Sidak’s post-hoc multiple comparison test to compare Tac and CR diversity 
at each time point. D. Beta diversity (sample dissimilarity) between Tac and CR 
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mice during Py infection using the Bray-Curtis distance metric; each time point is 
compared to the respective Day 0 time point. Data were analyzed by one-way 
ANOVA with Dunnett’s post-hoc multiple comparison test. E. Matched beta 
diversity comparisons between Tac and CR mice at each time point. Data were 
analyzed by one-way ANOVA with Dunnett’s post-hoc multiple comparison test. 
F. Bacterial community alpha diversity from fecal pellets taken from mice 
receiving cecal contents. Data were analyzed by unpaired two-tailed t test. G. 
Bacterial community beta diversity from fecal pellets taken from mice receiving 
cecal contents. The comparisons are Tac control vs Tac control, GF+PyTac vs 
Tac control, CR control vs CR control, and GF+PyCR vs CR control. Data were 
analyzed by unpaired two-tailed t test. H. Parasitemia of GF mice gavaged with 
post-Py Tac or post-Py CR cecal contents along with controls. I. AUC of the 
parasite burdens shown in panel H. Data were analyzed by unpaired two-tailed t 
test. Data (mean±SE) in panels B-G are from one experiment (4-5 mice per 
group); panels H-I are cumulative results of 2 experiments (4-5 
mice/group/experiment). 1 symbol, p < 0.05; 2 symbols, p < 0.01; 3 symbols, p < 
0.001; 4 symbols, p < 0.0001; ns = not significant. * = Tac and CR comparisons; 




Figure 3-4. Metabolite profiles in selected tissues during Py infection. 
Principal Component Analysis (PCA) plot showing similarity of metabolite profiles 
in Tac and CR samples in the small intestine A., cecum C., and plasma E. 
Ellipses contain the 90% confidence area of each group. Metabolite profile 
heatmap from the small intestine B., cecum D., and plasma F. Sample group 
averages and metabolites are clustered using Ward’s method and Euclidean 
distance measure. Data are the cumulative results of 2 experiments (3 
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Figure 3-5. Severity of liver damage following Py infection correlates with 
both parasitemia burden and kinetics. Histology of representative livers (3 
mice/group/time point) stained with H&E in naive and Py-infected mice. Scale bar 
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= 100 µm; magnification = 20x. Arrowheads indicate hemozoin deposition; 
arrows indicate immune cell infiltration. 
 
 
Figure 3-6. Severity of Py infection correlates with loss of specific cecal 
bile acids. A. Small intestine bile acid heatmap. B. Cecal bile acid heatmap. C. 
Plasma bile acid heatmap. Data are cumulative over 2 experiments (3 
mice/group/experiment). Scale bars indicate scaled relative abundance of bile 
acids. aMCA = alpha-muricholic acid; bMCA = beta-muricholic acid; CDCA = 
chenodeoxycholic acid; CA = cholic acid; GCDCA = glycochenodeoxycholic acid; 
GCA = glycocholic acid; GDCA = glycodeoxycholic acid; HDCA = hyodeoxycholic 
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acid; oMCA = omega-muricholic acid; TCDCA = taurochenodeoxycholic acid; 




Figure 3-7. Severe Py infection increases the predicted functional capacity 
of the gut microbiota. A. KO proportions and total abundance in the Tac cecal 
microbiota at day 0 p.i. B. KO proportions and total abundance in the CR cecal 
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microbiota at day 0 p.i. C. KO abundances during Py infection classified to the 
level 1 KEGG category “Metabolism” between Tac and CR microbiota. D. KO 
abundances during Py infection classified to the level 1 KEGG category “Cell 
Processes” between the Tac and CR microbiota. E. KO abundances during Py 
infection classified to the level 2 KEGG category “Cell Motility” between the Tac 
and CR microbiota. F. KO abundances of the “Amino Acid metabolism” category 
during Py infection. G. Cecal metabolite pathway enrichment between Tac and 
CR mice at day 0 p.i. Blue means a pathway is enriched in Tac while red is 
enriched in CR; purple indicates enrichment in both. H. Cecal metabolite pathway 
enrichment at day 21 p.i. Arrows represent pathways that were enriched in Tac at 
ay 0 p.i. but are enriched in CR at day 21 p.i. and vice versa. Data in C-F were 
analyzed by unpaired two-tailed t-test. G-H. Data were analyzed using 
Metaboanalyst’s Enrichment Analysis based on the globaltest algorithm and are 
Holm-Bonferroni adjusted. Data (mean±SE) originate from Figure S3 samples 
and are cumulative results (n=2-3 mice/group/experiment) of two experiments. 1 
symbol, p < 0.05; 2 symbols, p < 0.01; 3 symbols, p < 0.001; 4 symbols, p < 
0.0001. * = Tac and CR comparisons; a = Tac comparisons with Day 0; b = CR 
comparisons with Day 0. 
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Figure 3-8. Schematic of the different host and microbiota factors. Arrows 
represent the ability of one factor to influence another. Colors represent 
differential effects driven by low or high parasitemia. 
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Figure 3-9. Gating strategies from the LP of mouse SI and LI. A. Gating 
strategy of single cell suspension and CD45+ cells. B. Gating strategy for CD4+ 
and CD8+ T cells. C. Gating strategy for TCR𝛾𝛿 T cells and IL17+ TCR𝛾𝛿 T cells. 
D. Gating strategy for Tregs, Th17 T cells, and IL17+ Th17 T cells. E. Gating 
strategy for neutrophils, monocytes, and macrophages. 
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Figure 3-10. Large intestine lamina propria immune system changes during 
Py infection. Total cell numbers of A. CD45+ cells, B. CD8+ T cells, C. CD4+ T 
cells, D. Tregs, E. Gamma delta T cells (TCR𝛾𝛿), F. IL17+ TCR𝛾𝛿 G. Th17 cells, 
H. IL17+ Th17 cells, I. Macrophages, J. Monocytes, and K. Neutrophils. Each 
time point was compared by one-way ANOVA with Tukey’s post-hoc multiple 
comparison test. Data (mean±SE) are cumulative results of 2 experiments (3 
mice/group/experiment). 1 symbol, p < 0.05; 2 symbols, p < 0.01; 3 symbols, p < 
0.001; 4 symbols, p < 0.0001. * = Tac and CR LI comparisons; a = Tac LI 
comparisons to Day 0; b = CR LI comparisons to Day 0. 
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Figure 3-11. The composition of gut bacteria populations changes after 
clearance of Py. A. Relative taxonomic abundance of bacterial families during 
Py infection. c = class, o = order. B. Alpha diversity (sample richness) between 
Tac and CR mice during infection using the Chao1 metric. C. Beta diversity 
(sample dissimilarity) between Tac and CR mice during Py infection using the 
Bray-Curtis distance metric; each time point is compared to the respective Day 0 
time point. Data in B-C were analyzed by one-way ANOVA with Dunnett’s post-
hoc multiple comparison test. Data (mean±SE) are cumulative results of 2 
experiments (2-3 mice/group/experiment). *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001; ns= not significant. 
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Figure 3-12. Small intestine bile acid profiles over Py infection. aMCA = 
alpha-muricholic acid; bMCA = beta-muricholic acid; CDCA = chenodeoxycholic 
acid; CA = cholic acid; GCDCA = glycochenodeoxycholic acid; GCA = 
glycocholic acid; GDCA = glycodeoxycholic acid; HDCA = hyodeoxycholic acid; 
oMCA = omega-muricholic acid; TCDCA = taurochenodeoxycholic acid; TCA = 
taurocholic acid; TDCA = taurodeoxycholic acid; TMCA = tauromuricholic acid. 
Data were analyzed by unpaired t-test. Data (mean±SE) are cumulative results 
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(n=3 mice/group/experiment) of two experiments. 1 symbol, p < 0.05; 2 symbols, 
p < 0.01; 3 symbols, p < 0.001; 4 symbols, p < 0.0001. * = Tac and CR 
comparisons; a = Tac comparisons with Day 0; b = CR comparisons with Day 0. 
 
 
Figure 3-13. Cecal bile acid profiles over Py infection. aMCA = alpha-
muricholic acid; bMCA = beta-muricholic acid; CDCA = chenodeoxycholic acid; 
CA = cholic acid; GCDCA = glycochenodeoxycholic acid; GCA = glycocholic 
acid; GDCA = glycodeoxycholic acid; HDCA = hyodeoxycholic acid; oMCA = 
omega-muricholic acid; TCDCA = taurochenodeoxycholic acid; TCA = 
taurocholic acid; TDCA = taurodeoxycholic acid; TMCA = tauromuricholic acid. 
Data were analyzed by unpaired t-test. Data (mean±SE) are cumulative results 
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(n=3 mice/group/experiment) of two experiments. 1 symbol, p < 0.05; 2 symbols, 
p < 0.01; 3 symbols, p < 0.001; 4 symbols, p < 0.0001. * = Tac and CR 
comparisons; a = Tac comparisons with Day 0; b = CR comparisons with Day 0. 
 
 
Figure 3-14. Plasma bile acid profiles over Py infection. aMCA = alpha-
muricholic acid; bMCA = beta-muricholic acid; CDCA = chenodeoxycholic acid; 
CA = cholic acid; GCDCA = glycochenodeoxycholic acid; GCA = glycocholic 
acid; GDCA = glycodeoxycholic acid; HDCA = hyodeoxycholic acid; oMCA = 
omega-muricholic acid. Data were analyzed by unpaired t-test. Data (mean±SE) 
are cumulative results (n=3 mice/group/experiment) of two experiments. 1 
symbol, p < 0.05; 2 symbols, p < 0.01; 3 symbols, p < 0.001; 4 symbols, p < 
0.0001. * = Tac and CR comparisons; a = Tac comparisons with Day 0; b = CR 
comparisons with Day 0.
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CHAPTER 4 
ORAL ADMINISTRATION OF CLINICALLY RELEVANT ANTIMALARIAL 
DRUGS DOES NOT MODIFY THE MURINE GUT MICROBIOTA 
 
 Malaria is an infectious disease responsible for the death of around 
450,000 people annually. As an effective vaccine against the parasite that 
causes malaria is not available, antimalarial drug treatments are critical in fighting 
the disease. Previous data has shown that the gut microbiota is important in 
modulating the severity of malaria. Although it is well appreciated that antibiotics 
substantially alter the gut microbiota, it is unknown how antimalarial drugs impact 
the microbiota. We show here that the two commonly used artemisinin 
combination therapies of artesunate plus amodiaquine and artemether plus 
lumefantrine do not change the gut microbiota. The overall relative species 
abundance and alpha diversity remained stable after treatment, while beta 
diversity analysis showed minimal changes after cessation of drug treatment, 
which were transient and quickly returned to baseline. Taken together, 
antimalarial drug administration does not affect the gut microbiota.
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Introduction 
 Plasmodium is a significant global pathogen which infected 216 million 
people and caused 445,000 deaths in 2016; in sub-Saharan Africa, children 
under the age of 5 years old are the most vulnerable1. Currently, there is no 
effective vaccine against Plasmodium. Although there is growing resistance to 
frontline antimalarial drugs, particularly in Southeast Asia124,176, these drugs are 
still critical for treating those infected with Plasmodium. The gold standard for 
malaria treatment is artemisinin combination therapy (ACT). Artemisinin itself 
was originally isolated from the plant Artemisia annua in 1972 and has several 
semi-synthetic derivatives, including artemether, artesunate, and 
dihydroartemisinin177. Pharmacologically, these derivatives are more effective at 
clearing Plasmodium parasites than other anti-malarial drugs but tend to have 
shorter half-lives178. Consequently, artemisinin derivatives are usually combined 
with another anti-malarial drug that has a longer half-life to create an ACT to 
ensure continual parasite eradication and reduce instances of resistance to 
antimalarial drugs. Two of the most common ACTs are artemether combined with 
lumefantrine and artesunate combined with amodiaquine; these are commonly 
given orally but can also be administered intravenously, rectally, or 
intramuscularly20. 
 The mechanism of action for artemisinin and its derivatives has recently 
been shown to involve cellular damage in Plasmodium-infected red blood cells 
(iRBCs) along with inhibition of the proteasome; this leads to endoplasmic 
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reticulum stress and the buildup of damaged proteins55. In vitro experiments have 
also shown that artesunate can generate reactive oxygen species within iRBCs 
that lead to caspase activation and apoptosis56. The mechanisms for 
lumefantrine and amodiaquine are currently unknown, but it is suspected that 
both drugs interfere with Plasmodium’s ability to detoxify heme54. Both types of 
mechanisms of action synergize to give ACTs their effectiveness in treating 
malaria. 
 Previous research has shown antibacterial effects of artemisinin and its 
derivatives on specific pathogens. Derivatives of artemisinin were shown to be 
differentially effective at killing various fungi and bacteria, including methicillin-
resistant Staphylococcus aureus (MRSA)57. Additionally, encapsulation of 
artemisinin with beta-cyclodextrin enhances its antibacterial capacity when tested 
against MRSA179. While modifying artemisinin and its derivatives increases the 
antibacterial efficacy, these modified derivatives are not used clinically. However, 
unmodified artemether and artemisinin have been shown to be relatively potent 
at killing Helicobacter pylori, which is a human pathobiont57,58.  
 The gut microbiota has been shown to be important for many aspects of 
health and disease, including malaria. We have previously shown in mice that the 
gut microbiota can modulate the severity of infection, and modifying the 
microbiota through something as simple as changing the diet was sufficient to 
make mice susceptible to severe malaria136. Whereas oral antibiotic treatment 
has profound effects on the gut microbiota, the impact of antimalarial treatment 
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on the gut microbiota is unknown. Using a mouse model, we show that two 




Treatment with Clinically Relevant Doses of ACTs does not Change the 
Taxonomic Composition of the Murine Gut Microbiota 
 To test our hypothesis, we used two common ACTs: artesunate combined 
with amodiaquine (AA) and artemether combined with lumefantrine (AL). Due to 
the hydrophobic nature of lumefantrine, AL was dissolved in olive oil (O), while 
AA was dissolved in saline (H). The ACTs and vehicle controls were given by 
oral gavage daily for three days, similar to clinical practice. Fecal pellets were 
collected before treatment (day 0) and at days 1, 2, 3, 5, 7, 10, 14, and 21 post-
treatment (p.t.) (Fig. 4-1A). 
 Overall, the relative abundance of bacterial species remains consistent 
over treatments when compared to the pooled, pretreatment day 0 samples (Fig. 
4-1B). When the Bray-Curtis beta diversity is viewed in a PCoA plot and the 
samples are colored by time p.t., there is no appreciable separation between any 
of the time points, indicating high similarity (Fig. 4-1C). Whereas a separation 
between two populations can be seen in the panel displaying PC2 vs PC3 (Fig. 
4-1C), this separation is not attributed to any of the treatments or time points but 
rather due to variability between the first and second experiments. The overall 
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variability is small (12.16%) and is explained by the presence or absence of a 
small handful of species in one experiment. Within each experiment, there is no 
discernable pattern between the different time points p.t. Similarly, when the 
samples are colored by treatment received (Fig. 4-1D), there are no major 
differences, indicating neither ACTs or vehicle treatments lead to major changes. 
Overall, when comparing the relative taxonomic abundances and beta diversity 
plots, there are no consistent patterns indicating changes due to antimalarial 
treatment. 
 
Antimalarial Treatments do not Affect the Overall Diversity of the Murine 
Gut Microbiota 
 Alpha diversity analysis (measured by the number of observed OTUs per 
sample) of samples from mice treated with AA and the vehicle control, H, shows 
that the species composition does not change significantly over the course of the 
experiment (Fig 4-2A, B). For the beta diversity/dissimilarity comparisons, the 
day 0 p.t. within-group dissimilarity is compared to either the dissimilarity 
between the day 0 samples and the H-treated mice or between the day 0 
samples and the AA-treated mice, with higher beta diversity indicating greater 
dissimilarity. This comparison will identify time points in either the H- or AA-
treated mice that become more or less similar to the pre-treatment day 0 
bacterial communities following treatments, designated here as the “day 0 
comparison”. In this case, neither H nor AA caused the gut microbiota to change 
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from the day 0 baseline (Fig. 4-2C). The day 0 comparisons are then compared 
between treatments at each time point; this “treatment comparison” identifies 
dissimilarities in the gut microbiotas between treated and untreated mice even if 
there are no significant differences in the day 0 comparisons. Even though mice 
treated with H or AA show no significant day 0 comparisons, there are significant 
differences between the treatment groups at days 7 and 10 p.t., with the H 
treatment having a modestly higher Bray-Curtis distance (Fig. 4-2C). The lack of 
significance of the day 0 comparisons at these time points indicates that the 
differences in treatment comparisons, while significant, are not biologically 
relevant. That these differences were not until 4 to 7 days post H- and AA-
treatment after the last treatments suggests that these differences were not 
attributed to treatments. 
 The next ACT examined was AL and its vehicle O. The alpha diversity for 
mice receiving either vehicle or AL again showed that there were no significant 
changes to the number of species found in the gut microbiota during the 
experiment (Fig. 4-2D, E). The day 0 comparisons of beta diversity found that 
several of both AL- and O-treated samples have a greater dissimilarity to the day 
0 composition than day 0 has internally at day 3 p.t. for both AL (0.3468 versus 
0.2974; p=0.0011) and O (0.3498 versus 0.2974; p=0.0002), day 5 p.t. for AL 
(0.3429 versus 0.2974; p=0.0032), and day 21 p.t. for O (0.3552 versus 0.2974; 
p<0.0001) (Fig. 4-2F). These differences indicate that there are significant, 
though modest, differences in the gut microbiota of these mice at the specified 
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time points. Based on this data, it can be concluded that the treatments are 
contributing to the observed changes. However, with the increase in dissimilarity 
at day 3 for both O and AL, it cannot be ruled out that the olive oil vehicle alone 
caused the difference. The treatment comparisons show significant differences 
between O and AL at days 5 and 21 p.t., with AL samples having higher 
dissimilarity at day 5 p.t. compared to O, and O samples having higher 
dissimilarity at day 21 p.t. (Fig. 4-2F). This is consistent with the previous 
findings from the day 0 comparison, as the time points that show significant 
differences in treatment dissimilarity are the same time points to be significantly 
different compared to day 0. However, it must also be pointed out that these time 
points occur at least three days after the last AL treatment and 19 days after the 
last O treatment, which is considerably later when compared to previous data 
examining diet- or antibiotic-induced changes to the gut microbiota13,14. 
Additionally, these differences, at least for AL, appear to be transient, occurring 
only at the single time point. When the data is considered as a whole, there are 
several significant but minor differences in the microbiotas of mice treated with 
antimalarials, but no robust, long-term changes are seen.  
 
Discussion 
 In this study, we have shown that treatment with common ACTs does not 
change the gut microbiota of mice. This is an important observation, given the 
widespread use of these antimalarials around the globe and the diverse effect of 
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the gut microbiota on the host, including its ability to shape the severity of 
malaria136. Importantly, this work needs to be corroborated in humans, as mice 
and the murine gut microbiota are not perfect analogs of humans.  
 Since the gut microbiota does not change appreciably, it does not appear 
that the antimalarial treatments affect the microbiota directly, despite previous 
research on the antibacterial effects of artemisinin and its derivatives57,58. 
However, in the context of an inflammatory disease like malaria that has been 
shown to have an effect on the composition of the gut microbiota37,38, 
antimalarials may in fact protect the microbiota. In a model of hepatitis, 
artesunate treatment inhibited production of inflammatory cytokines such as 
interferon gamma and tumor necrosis factor alpha while driving production of the 
anti-inflammatory IL-10180. The cytokine modulation was driven by inhibition of 
the NF-kB signaling pathway, as artesunate enhanced phosphorylation of the 
NF-kB pathway and signaling components in liver tissue180. In macrophages, 
artesunate has also been shown to block autophagy-dependent activation due to 
LPS and thus downstream production of inflammatory cytokines181. With this in 
mind, artemisinin and its derivatives may not only eliminate malaria parasites 
during infection but also have secondary effects in maintaining host gut 
homeostasis. 
 There is still much that is unknown about artemisinin and its interactions 
with Plasmodium. However, we have briefly shown that two of the most 
commonly used ACTs do not change the composition of the gut microbiota in 
  124 
mice. As the gut microbiota has become an important area of clinical 
investigation, it is beneficial to know that ACT treatments do not seem to pose 
the same challenges as antibiotic treatments to gut homeostasis and host health. 
However, given the differences between mice and humans, it is critical to 
continue characterizing the role of the human gut microbiota during malaria 
infection and treatment to enhance the effort to defeat malaria as a global 
pathogen. 
 
Materials and Methods 
Animals and Housing: 
 6 week old female C57BL/6 mice were purchased from Envigo 
(Indianapolis, IN). All mice were housed in a specific pathogen-free facility and 
acclimatized for a minimum of 7 days before starting experiments. Animals were 
fed the NIH-31 diet (Modified Open Formula Mouse/Rat Irradiated Diet; Harlan 
7913; Envigo, Indianapolis, IN) and provided autoclaved, non-acidified municipal 
water ad libitum. The mice were kept on a 12-hour light/dark cycle from 6 AM to 
6PM and 6PM to 6AM, respectively. All animal experiments were carried out at 
the University of Louisville in compliance with local and national regulations of 
laboratory animal welfare. Additionally, all animal care and use procedures were 




Gut Microbiota Analysis: 
Mouse fecal pellets were collected at days 0, 1, 2, 3, 5, 7, 10, 14, and 21 p.t. and 
flash frozen in liquid nitrogen followed by storage at -80°C. DNA was extracted 
using the QIAamp PowerFecal DNA kit (QIAGEN, Germantown, MD) according 
to the manufacturer’s instructions. DNA samples were then shipped overnight on 
ice to the Genome Technology Access Center at Washington University (GTAC, 
St. Louis, MO) for sequencing followed by analysis using MVRSION175. The OTU 
table received from GTAC was CSS normalized and analyzed within QIIME 
v1.9.1 to produce taxa plots and calculate alpha diversity and Bray-Curtis beta 
diversity170. 
 
Antimalarial Drug Treatments: 
 For both AL and AA, clinical dosing was used according to 
recommendations by the World Health Organization20. Artemether was given at 2 
mg/kg and lumefantrine at 12 mg/kg, while artesunate was given at 4 mg/kg and 
amodiaquine at 10mg/kg. AL and AA were diluted in either 100% olive oil 
(Kroger, Cincinnati, OH, USA) or saline (Teknova, Hollister, CA, USA), 
respectively. Mice received AL and AA by oral once daily for three days.  
 
Statistical Analysis: 
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Statistical analyses were performed using GraphPad Prism 7 software 
(GraphPad Software, La Jolla, CA, USA). Specific analyses are described in 
figure legends.  
 
Figures and Figure Legends 
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Figure 4-1. Relative bacterial abundances remain stable despite 
antimalarial treatments. A. Experimental design for antimalarial treatments and 
fecal pellet collections. B. Relative taxonomic abundances of bacterial species 
among different treatment groups. Time points are collapsed by average 
abundance and scaled to sum to 1. PCoA plots of Bray-Curtis distances between 
samples, with either C. time p.t. or D. treatment metadata distinguishing samples. 
Data are the cumulative results of 2 experiments (4 mice/group/experiment); 
untreated (day 0) data for each group is pooled. 
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Figure 4-2. Antimalarial drug treatments cause minor changes to the 
diversity indices of the gut microbiota in mice. Alpha diversity of the gut 
microbiota as measured by observed OTUs in mice treated with A. saline and B. 
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artesunate and amodiaquine. C. Bray-Curtis beta diversity for samples treated 
with either water or artesunate and amodiaquine. The distances compared are 
between the pooled day 0 samples and each treatment group at each time point 
followed by comparisons between treatments at each time point. D. Alpha 
diversity of samples from mice treated with olive oil and E. mice treated with 
artemether and lumefantrine. F. Bray-Curtis beta diversity comparisons for 
samples from mice treated with either olive oil or artemether and lumefantrine as 
in panel C. Data are the cumulative results of 2 experiments (4 
mice/group/experiment); untreated (day 0) data for each group is pooled. Data in 
A-B and D-E were analyzed by one-way ANOVA with Tukey’s multiple 
comparisons test; data in C and F were analyzed by one-way ANOVA with 
Dunnett’s multiple comparisons test followed by a two-tailed t test for treatment 
comparisons at each time point. * = comparison between same-day treatments; # 
= comparison between treatment day and day 0 p.t. 1 symbol = p<0.05; 2 
symbols = p<0.01; 3 symbols = p<0.001; 4 symbols = p<0.0001.
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CHAPTER 5 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
 It is critical to understand mechanisms of host resistance and Plasmodium 
disease pathogenesis. Identifying Plasmodium-host interactions that can be 
exploited for the production of antimalarial drugs or as vaccine candidates has 
always been a relevant strategy. However, since we have shown that the 
composition of the gut microbiota can modulate the severity of infection, the 
dimensionality and complexity of interactions increases to include Plasmodium, 
the host, and the microbiota. With this in mind, the search for malaria treatments 
is both easier and harder simultaneously. It is easier in that it may be possible to 
simply modulate the gut microbiota using a probiotic bacteria, prebiotic fiber, or 
metabolite to enhance the host response to malaria and inhibit the development 
of complicated malaria. On the other hand, antimalarial treatment design must 
also consider the microbiota and its effect not only on the severity of malaria, but 
also on other aspects of host physiology like metabolism or immunity. A 
treatment that affects 
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the composition of the microbiota also has the potential to change the future 
resistance or susceptibility to severe malaria.  
 On a smaller scale, the complete mechanism for how the gut microbiota 
can regulate the severity of malaria is still unknown. Based on the observations 
made here, there are differences in host immunity during Py infection that 
correlate to differences in the gut microbiota; however, despite the fact that the 
compositions of both Tac and CR microbiotas become more similar over 
infection, these changes do not modulate severity of infection. With this in mind, 
one possible conclusion is that instead it is the differential function of the Tac and 
CR microbiotas that is responsible for the modulation of malaria severity. For 
example, Tac and CR mice receive the same diet with the same nutrients, but 
the cecal metabolite profiles are dramatically different during infection despite the 
decreasing dissimilarity between Tac and CR microbiotas. If the functional 
differences lead to the observed differences in severity of malaria, the products 
of the microbiota metabolism quite possibly are the key link between the 
microbiota and the host. However, this metabolite still needs to be identified. 
 One potential method to identify these metabolites that contribute to either 
resistant or susceptible phenotypes would be to isolate cecal or fecal cell-free 
supernatants from Tac or CR mice. These supernatants could then be given 
orally to identify the total contribution of the metabolites, or the supernatants 
could be treated beforehand to narrow down the class of metabolites that are 
active. For example, enzymatic treatments, heat treatments, and size 
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fractionation would help identify whether the active metabolite or metabolites 
were a specific type of molecule, such as a nucleotide or peptide.  
 In germ-free mice, other options exist for identifying active microbes or 
metabolites in resistance or susceptibility. First, limited colonization of gnotobiotic 
mice with microbes of interest, such as Lactobacillus or Bifidobacteria species, 
would help determine the contribution of specific microbes or consortia of 
microbes to resistance or susceptibility. These microbes could have potential 
probiotic functionality for enhancing resistance to malaria. One caveat, however, 
is that the contribution of probiotics that we observed was moderate at best, and 
primarily dependent on antibiotic treatment beforehand. While this does not 
preclude probiotics as a potential treatment, it does highlight the resiliency of the 
established microbiota and the difficulty such future treatments may face. In a 
similar vein, maintaining germ-free mice but treating with metabolites of interest 
or postbiotics from the resistant microbiota may aid in identifying signals from the 
microbiota that confer the resistant or susceptible phenotypes. Also, as diet was 
shown to influence susceptibility to severe malaria, mice could also be given 
diets restricted in certain metabolites such as specific amino acids or flavonoids. 
These diet studies would complement experiments where mice are given an 
abundance of a specific metabolite. 
 On a different note, we showed that treatment with ACTs has very limited 
effects on the gut microbiota. However, one way to confirm that these changes 
do not affect susceptibility to Py infections is to treat with ACTs followed by Py 
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infection; resistant and susceptible mice should have no changes in parasite 
burden or morbidity and mortality.  
 Within the context of human malaria, little work has been done to study 
how the gut microbiota modulates resistance or susceptibility to malaria. As 
discussed previously, different rodent models of malaria can recapitulate different 
aspects of human malaria; Py in particular can model the pathology and the initial 
immune response to malaria. Using mice with humanized microbiota would allow 
for initial characterization of how different human microbiota compositions 
modulate Py severity and the immune response to malaria. Comparisons could 
also be drawn between the baseline Tac or CR microbiota composition and 
function compared to the humanized microbiota. Prebiotic, probiotic, or antibiotic 
interventions could be used to modify the humanized microbiota to resemble the 
Tac microbiota to enhance resistance to Py. It would also be beneficial to 
perform large-scale sequencing efforts to identify microbiota profiles in humans 
that correlate with protection from malaria, as well as contributing factors like 
diet.  
 Overall, this work constitutes extensive characterization of how gut 
homeostasis affects and is affected by mild or severe Plasmodium infection, as 
well as a brief analysis of how clinical ACTs affect the composition of the gut 
microbiota. As the findings associated with the gut microbiota and its interactions 
with malaria are recent, it is hoped that these observations assist in future 
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